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ABSTRACT 
RECOMBINANT EXPRESSION AND POTENTIAL AUTOCATALYSIS OF 
AEDES AEGYPTI TRYPSIN-LIKE SERINE PROTEASES (AASPII AND AASPIV) 
by Diane Eilerts 
Aedes aegypti mosquitoes can be found globally in tropical and subtropical urban 
areas and spread Zika, Dengue fever, yellow fever, and Chikungunya viruses. Current 
vector control methods are limited and nonspecific. The female Ae. aegypti mosquito 
uses blood meal proteins to obtain nutrients required for oogenesis; inhibition of the 
midgut trypsin-like serine proteases responsible for blood meal digestion may provide a 
novel method of vector control. Ae. aegypti blood meal digestion is complex and the role 
of uncharacterized serine proteases in blood digestion is unclear; specifically, a group of 
trypsin-like serine proteases (AaSPII–V) is expressed at constant levels before and 
following Ae. aegypti blood meal acquisition. This research focuses on the in vitro 
biochemical study of two specific Ae. aegypti trypsin-like serine proteases (AaSPII and 
AaSPIV) in order to gain further understanding of their role in blood meal digestion. The 
approach involved the successful cloning and bacterial expression of these soluble, 
recombinant proteases. Results from attempts to purify these proteases were unsuccessful 
but indicative of potential autocatalytic and autodigestive behavior. Future studies will 
focus on obtaining purified recombinant proteases for further study. The study of AaSPII 
and AaSPIV, as well as other midgut Ae. aegypti  proteases, will aid in understanding the 
overall role proteases play in blood meal digestion and may eventually allow for the 
development of mosquito-specific enzyme inhibitors. 
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CHAPTER 1: INTRODUCTION 
1.1 Role of Aedes aegypti in Viral Pathogen Transmission 
Aedes aegypti mosquitoes have a complex life cycle with both aquatic and terrestrial 
stages (Figure 1).1 Adult female mosquitoes lay eggs in the walls of water-filled 
containers above the water’s surface.1 Even small amounts of water are sufficient for 
attracting female mosquitoes and eggs can survive desiccation and remain viable through 
cold and dry conditions for several months.1 Once the water level rises to cover the eggs, 
larvae emerge and feed on microorganisms present in the water. The larvae molt 3 times 
before transforming into pupae and continue to develop in the water.1 Adult flying 
mosquitoes (imago) emerge from pupal skin and leave the water environment.1 Both 
male and female mosquitoes feed on nectar, but only female mosquitoes require blood for 
egg production and after obtaining a blood meal will seek out water sources for an ideal 
environment to lay eggs.1 
 2
 
Figure 1. The Ae. aegypti life cycle showing aquatic and terrestrial stages. Female 
mosquitoes lay eggs in the walls of water-filled containers. When eggs are covered with 
water, larvae emerge. Larvae eventually transform into pupae and develop into adult 
mosquitoes. Public domain image by Mariana Ruiz Villarreal.  
Ae. aegypti mosquitoes act as vectors of the viral pathogens Zika, Dengue fever, 
yellow fever, and Chikungunya viruses, which can cause numerous human diseases.2 
When mosquitoes acquire a blood meal from an infected host, they too become infected; 
after an incubation period in which the pathogen can develop and replicate within 
mosquitoes, they can transmit these pathogens to a new host during later blood meal 
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acquisition.2 Humans remain the primary amplifying host for such viruses.3 Several 
factors are thought to contribute to the anthropophilic nature of Ae. aegypti mosquitoes. 
Research suggests that the evolution of Ae. aegypti mosquitoes to preferentially feed on 
humans may be linked to increases in the expression and ligand-sensitivity of a specific 
odorant receptor for sulcatone, an odorant primarily associated with humans.4 Feeding on 
humans (as opposed to primates or other vertebrates) benefits mosquito fitness for several 
reasons: (1) humans are hairless, making it easier to obtain a blood meal, (2) humans 
have a tendency to live in large groups, making food sources abundant for mosquitoes, 
and (3) humans typically provide adequate environments for mosquito eggs by collecting 
water, storing water, and producing debris that collects water.4 Therefore, feeding 
preferentially on humans may provide Ae. aegypti mosquitoes with greater reproductive 
fitness. Ae. aegypti mosquitoes live and thrive in tropical, subtropical, and temperate 
urban and semi-urban areas.3 Due to its anthropophilic nature, tendency to bite multiple 
times before oogenesis completion, and propensity to live in highly populated areas, the 
Ae. aegypti mosquito is a highly efficient vector.3 
1.1.1 Zika 
The Zika flavivirus (ZIKV) is primarily transmitted by infected Ae. aegypti mosquitoes; 
however, sexual transmission of ZIKV has also been reported.5,6 There is currently no 
vaccine available but symptoms are typically mild, usually lasting for 2 to 7 days and 
consisting of fever, rash, conjunctivitis, pain, malaise, and headache.5 Additionally, Zika 
infection in pregnant women has recently been associated with various birth defects in 
offspring including microcephaly and Guillain-Barré syndrome.7,8 Microcephaly is a birth 
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defect causing a baby’s head to be much smaller in size than expected.9 Microcephaly 
occurs when a baby’s brain does not develop properly during pregnancy or stops growing 
after birth. Several problems can be associated with microcephaly, including seizures, 
developmental delays, intellectual disability, problems swallowing, hearing loss, and 
vision issues. Severity ranges but problems are typically lifelong and often life 
threatening.9 Guillain-Barré syndrome is a disorder in which the body’s immune system 
attacks the peripheral nervous system; it is the most severe acute paralytic neuropathy 
and consists of several variants.10 Up to 30% of all cases manifest as severe Guillain-
Barré syndrome with respiratory failure. Initial symptoms include weakness and tingling 
in extremities and can quickly worsen, leading to paralysis. While most people recover 
from Guillain-Barré syndrome, some people experience continued symptoms.10 There is 
no cure for microcephaly or for Guillain-Barré syndrome.9,10 Zika virus is endemic in 
several areas within Africa and Asia (Figure 2).5 More recently, locally acquired Zika has 
also been reported in the Americas and even in the continental United States in Florida 
and Texas (Figure 3).5,11  
 5
 
Figure 2. Global Distribution of Zika virus transmission. Figure obtained from the Centers for Disease Control and Prevention.  
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Figure 3. Distribution of Zika virus in the United States. Laboratory-confirmed Zika virus disease cases by state as of January 
11, 2017. Degree of shading indicates density of cases reported. Figure obtained from the Centers for Disease Control and 
Prevention.
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1.1.2 Dengue  
Dengue virus (DENV) is an RNA flavivirus consisting of five serotypes (DEN-1, 
DEN-2, DEN-3, DEN-4, and the recently discovered DEN-5) primarily transmitted by 
Ae. aegypti mosquitoes.3,12 Dengue fever, which can result from infection by DENV, 
causes flu-like symptoms (fever, headache, severe pain, rash, bleeding) and has potential 
to develop into severe dengue (or Dengue Hemorrhagic Fever), a lethal complication 
characterized by massive bleeding and shock.13 There is extensive genetic variability 
among the five serotypes, making vaccine development challenging.13 Because the virus 
has multiple serotypes, those who recover from dengue fever and gain immunity to a 
particular serotype can still fall victim to subsequent infection by another serotype; 
unfortunately, consecutive dengue infection by multiple virus serotypes increases the risk 
of severe dengue.13  
Because dengue cases are severely underreported and often misdiagnosed, actual 
dengue infection incidence cannot be accurately determined.13 A 2012 study estimates 
that approximately 3.9 billion people in 128 countries are at risk of dengue infection.14 
Furthermore, a 2013 estimate suggests that approximately 390 million dengue infections 
occur annually, with approximately 96 million manifesting clinical symptoms.15 Cases of 
imported dengue infections have been reported throughout Mexico and the United States; 
instances of locally acquired dengue confirmed by the CDC have occurred in Florida, 
Texas, Hawaii, and even New York.16 Increasing air travel and globalization will 
continue to impact the distribution of dengue throughout the United States, especially in 
southern border states like California, Arizona, and Texas (Figure 4).16
 8
 
Figure 4. Distribution of Dengue in the United States. Shading indicates regions of imported and/or locally acquired dengue 
cases in the United States confirmed by the CDC between 2010 and 2014. Values indicate the number of imported dengue 
cases reported and locally acquired cases (parentheses) reported. Hashed area represents areas at risk based on 2013 vector 
distribution estimates. Reprinted with permission from Fredericks and Fernandez-Sesma16; DOI: 
http://dx.doi.org/10.1016/j.aogh.2015.02.006 in accordance with Creative Commons user license: 
https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode. 
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1.1.3 Yellow Fever  
The yellow fever flavivirus (YFV) is another viral pathogen transmitted by infected 
Ae. aegypti  mosquitoes. Fever, headache, jaundice, pain, nausea, vomiting, and fatigue 
are symptoms of yellow fever infection.17 Yellow fever virus is endemic in tropical 
regions of Africa as well as in Central and South America (Figures 5 and 6).17 While 
most patients see symptoms disappear within 3 to 4 days, a small portion of those 
infected succumb to a second, more toxic phase following the initial recovery in which 
high fever, jaundice, and bleeding occur.17 Approximately half of the patients who enter 
the toxic phase will die within 7 to 10 days.17 Fortunately, a highly effective, safe, and 
affordable vaccine against the yellow fever virus is available and provides lifelong 
immunity to yellow fever disease.17
 10
 
Figure 5. Distribution of yellow fever in Africa. Figure obtained from the Centers for Disease Control and Prevention.   
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Figure 6. Distribution of yellow fever in South America. Figure obtained from the 
Centers for Disease Control and Prevention.  
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1.1.4 Chikungunya  
Chikungunya virus (CHIKV) is an alphavirus transmitted by infected Ae. aegypti 
mosquitoes; the disease shares many of the symptoms associated with dengue (fever, 
joint pain, headache, nausea, fatigue, and rash).18 There is no vaccine or antiviral 
treatment available for chikungunya so treatment focuses only on symptoms of the 
disease.18 Joint pain associated with chikungunya can be extremely debilitating and can 
persist for months or even years. The name “chikungunya” originates from Makonde (or 
Kimakonde) root word kungunyala, meaning “to become contorted,” and describes the 
stooped posture of those suffering from the associated extreme joint pain. Chikungunya 
has been identified in more than 60 countries within Asia, Africa, Europe, and North and 
South America (Figure 7).18 Many individuals living in areas with endemic chikungunya 
depend on manual labor to support themselves and their families. While patients usually 
recover from chikungunya infection, the temporary inability to work can have detrimental 
effects on these impoverished populations. Cases of imported chikungunya have been 
reported in Canada, Mexico, and the United States.18 Twelve locally acquired cases of 
chikungunya were reported in Florida in 2014 and one was reported in Texas in 2015.19  
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Figure 7. Global distribution of Chikungunya. Countries and territories in which locally acquired chikungunya cases have 
been reported as of April 22, 2016. Figure obtained from the Centers for Disease Control and Prevention.  
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1.2 Vector Control Strategies 
Ae. aegypti mosquito populations are spreading worldwide and are predicted to 
continue to spread as temperatures rise due to climate change, creating more 
environments ideal for mosquitoes and increasing human exposure to the mosquito.20,21 
With no effective treatment for Dengue, Zika, or Chikungunya infection, no vaccines 
available to combat these viruses, and a relentless increase in vector-borne disease cases 
reported globally, there is a vital need to control the disease through the only available 
method: vector control.3,15,22,23 
1.2.1 Current Methods  
Current vector control strategies include environmental management, and biological 
and chemical methods.3 Environmental management techniques aim to alter controllable 
factors that contribute to the presence of available larval habitats for Ae. aegypti 
populations.3 As such, mosquito population prevalence is often correlated to poor water 
supply, sanitation, and waste disposal, which these environmental management 
techniques are designed to address.3 When properly applied, these methods can 
significantly reduce mosquito populations. However, these methods have obvious 
limitations: they are dependent on human behavior and awareness, requiring that all 
individuals of a population be knowledgeable of these practices, and can be ineffective in 
areas containing natural water reservoirs (tree or rock holes). Additionally, environmental 
management can be difficult to successfully implement in underdeveloped areas or in 
areas with limited resources. 
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Biological control of vector populations utilizes known ecological species 
interactions to decrease target mosquito populations by introducing predatory, competing, 
parasitic, or pathogenic organisms into the ecosystem.3 However, these methods are often 
impractical to employ in many urban settings and can have adverse effects on 
ecosystems.3 Recent studies suggest that release of genetically modified male Ae. aegypti 
mosquitoes carrying a homozygous dominant lethal gene can reduce mosquito 
populations; the transgenic males can compete with native male mosquitoes and 
procreate with female mosquitoes to produce offspring with an expressed lethal gene that 
causes death in embryonic or larval stages.24 While initial studies appear promising, 
research has been limited and public opinion of the practice can be extremely 
controversial; there is also uncertainty in the future of research and implementation of 
this method due to issues associated with regulation.25,26 Until further research is 
conducted, it is unclear whether the use of genetically modified mosquitoes would be a 
viable option to control mosquito populations. Another biological method gaining in 
notoriety involves releasing Ae. aegypti mosquitoes that have been experimentally 
infected with specific strains of Wolbachia (a bacterial symbiont) to establish long-term 
infection in the mosquito population.27 Infection by Wolbachia has been shown to reduce 
Ae. aegypti life span, egg viability, and blood feeding success in addition to increasing 
mosquito resistance to DENV infection.27 While this method of vector control may have 
potential to positively impact human health, the effectiveness varies for various DENV 
serotypes and it would likely be insufficient in high-transmission areas.27 Biological 
methods are typically expensive and impractical to implement at large scales and benefits 
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outweighing potential damage to ecosystems are often short-sighted since mosquito 
populations usually recover. 
Chemical vector control methods depend on the use of insecticides, which can either 
target mosquito larvae (larvicides) or adult mosquitoes (adulticides). Insecticides act as 
neurotoxicants, disturbing calcium homeostasis and other molecular mechanisms, which 
are not species-specific.28 There are numerous types of insecticides, classified by 
chemical structure and mode of action: pyrethroids cause voltage-gated sodium channels 
to remain activated; organophosphates irreversibly inhibit the enzyme 
acetylcholinesterase; organochlorine insecticides can target voltage-gated sodium 
channels or receptors that respond to either glycine or to the neurotransmitter 
gamma-aminobutyric acid (GABA); neonicotinoids target nicotinic acetylcholine 
receptors.28 While insecticides currently act as the most potent tool available for 
controlling mosquito populations, insecticides should only be used in emergencies or in 
situations in which no other methods would be beneficial. Since insecticides are not 
species-specific, they can be toxic to humans and other ecologically significant 
populations. Pesticide use has been known to have devastating off-target effects on other 
animals, including honeybees and other pollinators.29,30 Another concern associated with 
reliance on insecticides is the growing trend of mosquitoes exhibiting insecticide 
resistance. The increasing frequency of Ae. aegypti insecticide resistance necessitates 
research towards the development of novel vector control methods that do not drive 
mosquito evolution towards resistance.2,3,31-34 New methods to address vector control are 
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vitally needed due to increased pathogen drug resistance, lack of effective disease 
treatment or vaccine options, and increased insecticide resistance.2 
1.2.2 Ae. aegypti Midgut Serine Proteases  
A human blood meal is required by female Ae. aegypti mosquitoes to supply the 
nutrients necessary for metabolism and oogenesis.35 Digestion of blood proteins occurs in 
the midgut via proteases: a dramatic increase in protease activity occurs in the Ae. aegypti 
midgut upon blood intake.36,37 Proteases are proteolytic enzymes that release an amino 
acid or peptide from a larger peptide or protein; endopeptidases act on internal peptide 
bonds while exopeptidases act on the peptide bonds of amino acids at the N- or 
C-terminus.38 Within the Ae. aegypti midgut, serine proteases, in addition to 
exopeptidases, are responsible for the rapid digestion of blood and, thus, contribute to 
mosquito fecundity.35 Inhibiting the activity of proteases necessary for blood meal 
digestion may be an effective way to manage mosquito populations and consequently, 
transmission of associated viral pathogens.  Previous research confirms that reducing the 
percentage of blood in the female mosquito blood meal significantly decreases the 
amount of viable eggs produced.22 By effectively inhibiting the digestion of blood meal 
proteins with synthetic peptide analog inhibitors, the mosquito would be unable to render 
nutrients from the blood necessary for egg development, reducing the population of 
future mosquito generations.  
Proteases have catalytic sites consisting of either amino acid or water nucleophiles.39 
Serine proteases are named for the nucleophilic serine residue in the enzyme active site.40 
The nucleophilicity of the serine hydroxyl group is dependent on aspartate and histidine 
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residues, which, along with serine, make up the catalytic triad or charge relay system 
(Ser-195, His-57, and Asp-102 according to bovine chymotrypsin numbering convention) 
(Figure 8).40 Compression of the hydrogen bond between the histidine and aspartate 
residue results in a low-barrier hydrogen bond, increasing the pKa of the histidine residue 
and allowing the histidine residue to act as an enhanced general base and hydrogen ion 
acceptor; the aspartate residue orientates the imidazolium ring of the histidine residue, 
making histidine a better proton acceptor and bringing serine and histidine into closer 
proximity.41 While the pKa value of a serine hydroxyl group is generally too high for 
deprotonation to be favorable in physiological conditions, this hydrogen bonding network 
results in polarization of the hydroxyl group of the serine residue side chain, which can 
then be deprotonated to prevent formation of an unfavorable positive charge on the serine 
hydroxyl group and makes the serine residue an extremely powerful nucleophile.38,41,42  
 
Figure 8. Catalytic Triad. The charged aspartic acid side chain orientates the 
imidiazolium ring of the histidine residue, which acts as a general base and can 
deprotonate the hydroxyl group on the serine residue, generating the alkoxide ion that can 
act as an extremely powerful nucleophile.  
The mechanism of peptide hydrolysis (Figure 9) proceeds in the following steps, 
beginning with (1) substrate binding, followed by (2) a nucleophilic attack on the 
substrate carbonyl carbon of the peptide bond by the activated hydroxyl group of serine 
195. This alters the geometry of atoms around the carbon, resulting in an unstable 
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tetrahedral intermediate with a negatively charged oxygen atom stabilized by the 
oxyanion hole (hydrogen bonding by backbone NH groups). Proton transfer from the 
histidine residue to the newly formed amino group (at the substrate cleavage site) leads to 
(3) collapse of the tetrahedral intermediate, producing the acyl-enzyme. The N-terminal 
region of the cleaved substrate can then (4) leave the enzyme active site and is then 
replaced by a water molecule. The water molecule attacks the carbonyl group and the 
histidine residue removes a proton, (5) forming a second tetrahedral intermediate. 
Collapse of the second tetrahedral intermediate leads to (6) formation and release of the 
carboxylic acid product. Afterwards, the enzyme catalyst is regenerated and ready for 
subsequent catalysis.42 This mechanism is common among all serine proteases, which 
include trypsin, chymotrypsin, elastase, and serine collagenase. Studies focusing on the 
Ae. aegypti mosquito have revealed that the major serine protease involved in the blood 
meal digestion process are trypsin-like enzymes.22,23  
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Figure 9. Serine protease enzyme mechanism. 
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Blood meal digestion in Ae. aegypti mosquitoes occurs in a biphasic manner; midgut 
trypsin-like activity increases during the early phase of digestion, 0 to 6 h post blood 
meal (PBM), and the late phase of digestion shows a more dramatic increase 12-18 h 
PBM.22,43 Three serine proteases showing the highest expression levels in female Ae. 
aegypti were initially characterized: early trypsin (AaET), late trypsin (AaLT), and 5G1 
(AaSPVI).43,44 Completion of the Ae. aegypti genome and subsequent bioinformatics 
analyses identified another abundant protease, AaSPVII, in addition to other midgut 
proteases.22,35,45 Of the hundreds of serine protease-like genes in the Ae. aegypti genome, 
66 were identified as potential trypsins and just nine of these were found to be expressed 
in the midgut.35,45 Trypsin belongs to the serine protease family [subclan PA(S)] and is 
vital in Ae. aegypti blood meal digestion.38,46 Trypsins cleave peptide substrates on the 
C-terminal side of lysine or arginine. Mammalian trypsins have the ability to activate 
trypsinogen, the zymogen form of trypsin; it has been proposed that mosquito trypsin-like 
serine proteases may also display autocatalytic behavior (autoactivation) but has not yet 
been shown definitively.44  
Knockdown studies of the four most abundant Ae. aegypti proteases have shown that 
only three have an effect on mosquito fecundity: AaLT, AaSPVI, and AaSPVII.22 While 
mRNA knockdown of each individual protease resulted in a decrease in the amount of 
eggs laid by the mosquito, knockdown of all three of these proteases at once did not have 
an overall additive decrease as expected.22 This suggests that other Ae. aegypti midgut 
enzymes may compensate for this loss of activity.22  
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In order to determine which proteases may play a significant role in this process, 
expression profiles were determined for the other nine Ae. aegypti midgut serine 
proteases.35 Expression profiles for Ae. aegypti serine proteases II–V (AaSP group I) 
show that these genes are expressed at constant levels before and after blood meal 
acquisition.35 Therefore, is possible that AaSP group I proteases may be responsible for 
protease activity observed following knockdown of abundant proteases.35 High sequence 
similarity between AaSP group I genes prevented researchers from determining 
individual gene transcript levels; instead, the cumulative level of AaSP group I genes 
were quantified from whole body Ae. aegypti genomic DNA libraries.35 Initial sequence 
analyses show that these enzymes are trypsin-like serine proteases each containing six 
cysteine residues corresponding to three highly conserved disulfide bonds; serine 
proteases II and IV (AaSPII and AaSPIV) sequences contain two additional cysteine 
residues for a total of four disulfide bonds in the native conformation.35 Sequence 
alignments show the AaSP group I genes belong to the same clade, with highest sequence 
similarity between AaSPII and AaSPIV (96% sequence identity).35 Therefore, the degree 
to which individual proteases belonging to the AaSP group I are expressed in the 
mosquito midgut remains unknown.35  
Results from mRNA knockdown experiments suggest that inhibiting blood meal 
metabolism in Ae. aegypti may additionally require inhibition of compensatory proteases. 
Such development of specific inhibitors requires prior biochemical studies aimed at 
enzyme characterization, which have not yet been performed for AaSP group I proteases 
and other proteases with lower expression levels. Specifically, AaSPII and AaSPIV are of 
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particular interest in this study. These genes will be cloned and studied in vitro to gain 
insight into their function and determine their potential roles in the Ae. aegypti blood 
meal process. 
1.3 Recombinant Protein Expression in Escherichia coli 
Natural protein quantities are often insufficient for biochemical study; instead, 
recombinant technologies are frequently used in biochemical research to obtain pure, 
soluble, and functional proteins of interest.47 Large quantities of recombinant protein for 
biochemical studies can be produced by utilizing simple prokaryotic organisms such as 
Escherichia coli and bacterial specific plasmid expression vectors.48 Expression using E. 
coli as the host is often employed; however, using prokaryotic expression systems for 
eukaryotic proteins may not always be successful and can cause expression of insoluble 
protein.47 The E. coli cytoplasm is maintained in a reduced state primarily through 
thioredoxin and glutaredoxin systems, which makes disulfide bond formation in proteins 
unfavorable.49-51 The thioredoxin system comprises of thioredoxin reductase and 
thioredoxin and the glutaredoxin system consists of glutathione reductase, glutathione, 
and three glutaredoxins.51 Both systems use NADPH to reduce disulfide bonds in 
enzymes expressed in the E. coli cytoplasm.51 Therefore, using E. coli to express proteins 
requiring multiple disulfide bonds, such as AaSPII and AaSPIV, to maintain structure and 
function may result in the expression of misfolded proteins (or inclusion bodies) when 
necessary disulfide bonds are reduced.47 Several strategies have been developed in an 
effort to overcome such obstacles in expressing eukaryotic recombinant protein and 
include both preventative and consequent techniques.47 Specifically, three subsets of 
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methods are commonly used to obtain soluble, active protein from E. coli: those that 
attempt to modify the in vivo parameters without modifying the target protein; those that 
involve modifying the target protein; and those that employ in vitro refolding methods.47 
Numerous strategies in which target modification is avoided exist and can include: 
cultivating bacteria at reduced temperatures, adjusting growth media components, using 
mutant E. coli strains engineered to promote solubility, or addition of appropriate binding 
cofactors, binding partners, or molecular chaperones.47 When these methods are 
unsuccessful, it may be necessary to engineer the target protein by attaching a more 
soluble species as a fusion protein.47 In cases of unavoidable protein aggregation and 
inclusion body formation, solubilization and refolding methods can be used; however, 
this often results in poor recovery or inactive enzyme.52  
1.4 Protein Purification Techniques 
Upon successful soluble protein expression, it is necessary to purify the target 
enzyme. Often, a series of purification steps are executed to ensure homogeneity of the 
final product.53 Ion exchange chromatography is one purification method that can be 
employed. Ion exchange chromatography separates proteins based on charge type and 
relative strength; it is dependent on the interaction between charged amino acid residues 
in the sample and ions in the column stationary phase.54 At physiological pH, the amino 
acids lysine, arginine, and histidine are positively charged while aspartate and glutamate 
are negatively charged. The overall charge of the target protein is dependent on pH and 
the amino acid sequence, which determines the protein’s isoelectric point (pI).   
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Another common method of protein purification is immobilized metal affinity 
chromatography (IMAC). Specific amino acids located on the protein surface can bind to 
certain metal ions; this interaction is exploited in IMAC for protein purification. Protein 
binding in IMAC is dependent on the histidine residues accessible on the protein’s 
surface, as histidine shows the strongest interaction with immobilized metal matrices due 
to the electron donating groups on the imidazole ring of histidine that readily coordinate 
with the metal.55-57 Histidine-tagged fusion proteins can be purified in this manner with 
the use of Ni(II) or other divalent ions. Histidine-tagged proteins can be applied to IMAC 
column matrices and impurities can be removed with washing; the target protein can then 
be eluted simply by adjusting the pH or adding free imidazole to the column.57 There are 
several advantages in using IMAC for purification; for example, there is usually low 
contamination from bacterial proteins due to the high selectivity of histidine-tagged 
protein to the metal.58  
Size-exclusion chromatography is another technique that can be used to purify 
proteins and is often employed as the final step in the purification process. In 
size-exclusion chromatography, sample components separate based on molecular size and 
shape; separation performed by size-exclusion chromatography is determined by the pore 
size of the column matrix.59 Larger proteins that cannot move through the pores instead 
travel around the matrix and elute prior to smaller proteins; because small proteins can fit 
through all of the pores in the matrix, they take a longer path and thus elute last.53 
Because purification is not dependent on binding of the target protein, this method is 
generally less susceptible to protein loss.53 
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1.5 Protease Characterization Techniques 
Upon successful purification of the target protein, biochemical methods of enzyme 
characterization can be performed. Trypsin-like activity can be efficiently measured 
using Nα-benzoyl-D,L-arginine-p-nitroanilide hydrochloride (BApNA), a synthetic 
colorimetric substrate for trypsin.43,60,61 Trypsin-like proteases will cleave BApNA to 
generate p-nitroaniline (pNA), which is yellow in color and can be detected at 410 nm; 
the color intensity of pNA is directly proportional to concentration, allowing for an 
accurate measurement of protease activity.60 Total enzyme activity can be determined by 
observing the production of pNA from BApNA via a UV-visible spectrophotometer and 
using the extinction coefficient, ε410nm = 9960 M-1cm-1.60  
Characterization typically also involves the determination of the three-dimensional 
enzyme structure in order to understand the catalytic mechanism, identify the enzyme 
active site, and determine the substrate binding mechanism for the potential development 
of inhibitors. The primary methods to determine protein structure at atomic resolution are 
protein crystallography and nuclear magnetic resonance (NMR) spectroscopy. Protein 
crystallography involves collecting data of an X-ray beam being diffracted by a protein 
crystal and can provide an electron density model of the crystal.62 Often, the most 
difficult aspect of protein crystallography is forming the crystal; proteins are large, 
irregularly shaped, and dynamic macromolecules that do not easily form an ordered 
crystal lattice.63 The greatest limitation of protein crystallography is that it requires 
crystallization of the protein, which renders the protein target immobile and may not be 
representative of dynamic protein structures in solution.  
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NMR spectroscopy can be applied to proteins in solution and uses radiowaves that 
interact with the protein in a strong magnetic field and can be used for proton 
localization, which can be difficult to determine via crystallography.62,64 Because it does 
not require protein crystallization, NMR spectroscopy can be used to study reaction 
kinetics and dynamics.65 However, proteins large in size can be extremely difficult to 
study using protein NMR as spectra become quite complex. Often, complementary 
techniques can be used for structure determination to resolve various aspects of protein 
structure.  
1.6 Specific Research Aims 
Research herein aims to understand the role of Ae. aegypti trypsin-like midgut serine 
proteases II and IV (AaSPII and AaSPIV). Specifically, in vitro biochemical studies of 
AaSPII and AaSPIV will involve successful cloning and bacterial expression of soluble, 
recombinant enzyme and protein purification in preparation for biochemical analyses. 
Studying AaSPII and AaSPIV, as well as other midgut Ae. aegypti  proteases, will aid in 
understanding the overall role of proteases involved in blood meal digestion and may 
eventually allow for the development of potential enzyme inhibitors to inhibit egg 
production, minimize mosquito populations, and hopefully lead to a decrease in viral 
pathogen transmission.  
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CHAPTER 2: METHODS 
2.1 Preparation of Protease Plasmid Constructs 
2.1.1 General Cloning Strategy 
Gene-specific polymerase chain reaction (PCR) primers for serine proteases AaSPII 
and AaSPIV were designed manually using a modified cloning PCR strategy to generate 
a gene product containing the appropriate base pair region encoding the AaSPII or 
AaSPIV gene from cDNA isolated from blood-fed mosquitoes (Table 1 and Table 2).66 
All primers were checked using NetPrimer 
(http://www.premierbiosoft.com/netprimer/netprlaunch/netprlaunch.html) for appropriate 
parameters including: length, melting temperature (Tm), potential hairpin and 
primer-dimer formation, and G-C content. 
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Table 1. Primers used for PCR amplification and cloning of recombinant forms of the 
full length zymogen (with leader), mature form (no leader), MBP-fusion, EK-pseudo 
propeptide, and mutant (Ser to Ala and Lys to Ala) AaSPII. 
Protease Leader  
Target 
Vector 
for 
Cloning 
Primer Primer Sequence 
AaSPII  
With 
Leader 
pET28a 
Fwd 
5'-AAAAAGCTAGCATGTGG 
TTTTCTGTGAAAATATCG -3' 
Rev 
5'- AAAAACTCGAGTTATT 
ACACAACCCAAACCGCTC -3' 
AaSPII 
No 
Leader 
pET28a 
Fwd 
5'- AAAAAGCTAGCATGTC 
GGTGGACAACGACGTG -3' 
Rev 
5'- AAAAACTCGAGTTATT 
ACACAACCCAAACCGCTC -3' 
EK-AaSPII 
No 
Leader 
pET28a 
Fwd 
5’- AAAAAGCTAGCAACAACA 
ACCTCGGCGATGACGATGACA 
AGATCATCGGTGGTTTTCCCG -3’ 
Rev 
5’- AAAAACTCGAGTTATTAC 
ACAACCCAAACCGCTC -3’  
MBP-
AaSPII 
No 
Leader 
pMAL-
c5E 
Fwd 
5'- AAAAACCATGGGCAGC 
AGCCATCATCATC -3' 
Rev 
5'- AAAAAGAATTCTTATTACA 
CAACCCAAACCGCTCT -3' 
AaSPII Ser 
to Ala 
Mutant 
No 
Leader 
pET28a 
Fwd 
5’- CTCTTGCCAGGGTGATGC 
CGGGGGTCCTTTGG -3’  
Rev 
5’- CCAAAGGACCCCCGGC 
ATCACCCTGGCAAGAG -3’  
AaSPII Lys 
to Ala 
Mutant 
No 
Leader 
pET28a 
Fwd 
5’- CGGTGGACAACGACGTG 
GCGATCATCGGTGGTTTTC -3’  
Rev 
5’- GAAAACCACCGATGATC 
GCCACGTCGTTGTCCACCG -3’  
AaSPII 
No 
Leader 
pET29b 
Fwd 
5'- AAAAACCATGGGCTCGG 
TGGACAACGACGTG -3' 
Rev 
5'- AAAAACTCGAGCACAAC 
CCAAACCGCTCTG -3' 
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Table 2. Primers used for PCR amplification and cloning of recombinant forms of the 
full length zymogen (with leader), mature form (no leader), MBP-fusion, EK-pseudo 
propeptide, and mutant (Ser to Ala and Lys to Ala) AaSPIV. 
Protease Leader  
Target 
Vector 
for 
Cloning 
Primer Primer Sequence 
AaSPIV 
With 
Leader 
pET28a 
Fwd 
5’- AAAAAGCTAGCATGTGGTTTT 
CTGTGAAAATATCG -3’ 
Rev 
5’- AAAAACTCGAGTTACACAACC 
CAAACCGCT -3’ 
AaSPIV 
No 
Leader 
pET28a 
Fwd 
5'- AAAAAGCTAGCATGTCGGTGG 
ACAACGACATGA -3' 
Rev 
5’- AAAAACTCGAGTTACACAACC 
CAAACCGCT -3’ 
EK-
AaSPIV 
With 
Leader 
pET28a 
Fwd 
5’-AAAAAGCTAGCAACAACAACC 
TCGGCGATGACGATGACAAGATCA
TCGGCGGTTTTCC-3’ 
Rev 
5’- AAAAACTCGAGTTACACAACC 
CAAACCGCT -3’  
MBP-
AaSPIV 
With 
Leader 
pMAL-
c5E 
Fwd 
5'- AAAAACCATGGGCAGCAGCCA 
TCATCATC -3' 
Rev 
5'- AAAAAGAATTCTTACACAACC 
CAAACCGCT  -3' 
AaSPIV 
Ser to Ala 
Mutant 
With 
Leader 
pET28a 
Fwd 
5’- CTCTTGCCAGGGTGATGCCGG 
GGGTCCTTTGG -3’  
Rev 
5’- CCAAAGGACCCCCGGCATCAC 
CCTGGCAAGAG -3’  
AaSPIV 
Lys to Ala 
Mutant 
With 
Leader 
pET28a 
Fwd 
5’- CGGTGGACAACGACATGGCGA 
TCATCGGCGGTTTTC -3’  
Rev 
5’- GAAAACCGCCGATGATCGCCA 
TGTCGTTGTCCACCG -3’ 
AaSPIV 
No 
Leader 
pET29b 
Fwd 
5'- AAAAACCATGGGCTCGGTGGA 
CAACGACATGAA -3' 
Rev 
5'- AAAAACTCGAGCACAACCCAA 
ACCGCTCTG -3' 
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PCR reactions were performed to obtain the target gene region. Each reaction 
contained 1X GoTaq Green Master Mix (Promega # M7128), 0.5 μM Forward Primer, 
0.5 μM Reverse Primer, 25 ng DNA template, and nuclease-free water to 15 μL. All PCR 
reactions were performed in an Eppendorf 5331 MasterCycler Gradient Thermal Cycler 
with cycling parameters as listed (Table 3).  
Table 3. Cycling Parameters for PCR amplification of recombinant forms of the full 
length zymogen (with leader), mature form (no leader), MBP-fusion, EK-pseudo 
propeptide, and mutant (Ser to Ala and Lys to Ala) AaSPII and AaSPIV. 
Steps Cycles Temperature Time 
Initial Denaturation 1 95 °C 5 min 
Denaturation 
25 
95 °C 20 s 
Annealing 58 °C 20 s 
Extension 72 °C 20 s 
Final Extension 1 72 °C 5 min 
Hold 1 20 °C HOLD 
 
PCR reaction success was evaluated by performing electrophoresis on reaction 
samples in a 1% agarose gel containing a 1:10000 dilution of GelRed Nucleic Acid Gel 
Stain (Biotium # 41002). The gel was then visualized by UV transillumination. Success 
of the PCR reactions was determined by the presence of a band near the correct 
molecular weight (predicted size of the PCR product) using a standard DNA ladder 
(Thermo Scientific GeneRuler 1 kb DNA Ladder, # SM0311). Successful PCR products 
were carefully excised and extracted from the gel using the Thermo Scientific GeneJET 
Gel Extraction Kit (# K0692) and eluting with 20 μL ultrapure water. The PCR products 
extracted from the gel were digested with 1 μL of each restriction enzyme (Thermo 
Scientific FastDigest restriction enzymes, details listed in following sections) and 1X 
FastDigest Buffer (Thermo Scientific # B64) prior to incubation at 37 °C for 1.5 h.   
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Vector digestion was performed in preparation for insertion of PCR products by 
combining 1000 ng vector, 1 μL of each restriction enzyme, 1X FastDigest Buffer 
(Thermo Scientific # B64), and nuclease-free water to 20 μL. The mixture was incubated 
at 37 °C for 1.5 h. Digestion mixture was then incubated at 90 °C for 10 min and then on 
ice for 1 min. Dephosphorylation of the digested vector was performed by adding 1 μL 
FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific # EF0654) and 
incubating for 1.5 h at 37 °C. Digested and dephosphorylated vector solutions were also 
run on a 1% agarose gel containing a 1:10000 dilution of GelRed Nucleic Acid Gel Stain 
(Biotium # 41002). Vector bands were excised from the gel and combined with digested 
PCR products and co-purified using the Thermo Scientific GeneJET Gel Extraction Kit 
(# K0692) and eluted with 20 μL nuclease-free water. 
Both vector and PCR product were digested with the same restriction enzymes in 
order to introduce the complimentary “sticky ends” to aid in successful ligation forming 
the plasmid of interest. PCR products and vector ligation was performed by adding 1 μL 
T4 DNA Ligase (NEB # M0202S) and 1X T4 DNA Ligase Reaction Buffer (NEB 
# B0202S) and incubating at room temperature for 20 min. 
NEB 10-beta Competent E. coli cells (# C3019H) were briefly thawed on ice in 
preparation for transformation of the ligated plasmid. Immediately after cells were 
thawed, 10 μL from the ligation reaction was added to the cells. The mixture was mixed 
by flicking the tube 4–5 times and incubated for 30 min on ice. Cells were heat shocked 
at 42 °C for 30 s and incubated on ice for 5 min. Cells were combined with 950 μL of 
SOC Outgrowth Media (NEB #B9020S) and incubated for 1 h in a 37 °C shaker 
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(250 RPM). Centrifugation at 13000 RPM for 1 min was then performed to pellet the 
cells and remove 900 μL of growth media. Cells were resuspended in remaining media 
and plated on agar containing an appropriate antibiotic [30 mg/mL kanamycin (the 
pET28a plasmid construct) or 100 μg/mL ampicillin or 50 μg/mL carbenicillin (either 
antibiotic is appropriate for selection of the pMAL-c5E plasmid construct)] to select for 
cells containing desired plasmid. Transformation plates were incubated overnight at the 
optimal growth temperature. Colonies were then restreaked onto fresh transformation 
plates and incubated overnight at the optimal growth temperature. The general cloning 
procedure is summarized in Figure 10. Colony PCR was performed for new “stock” 
bacterial plates from original transformation colonies to check for successful molecular 
cloning. For each “stock”, one PCR reaction was prepared by combining 1X GoTaq 
Green Master Mix (Promega # M7128), 0.5 μM Forward Primer, 0.5 μM Reverse Primer, 
and nuclease-free water to 15 μL with one colony from the restreaked plate. All PCR 
reactions were performed in an Eppendorf 5331 MasterCycler Gradient Thermal Cycler 
with cycling parameters as listed in Table 3 and reaction success was assessed via 1% 
agarose gel electrophoresis.  
For each sample with successful Colony PCR products, one colony was added to 
overnight cultures containing 25 mL Luria-Bertani (LB) broth with appropriate antibiotic 
for selection. Overnight cultures were incubated overnight (16–18 h) at the optimal 
growth temperature with shaking (250 RPM). Plasmids were isolated from cells grown 
overnight using the Thermo Scientific GeneJET Plasmid Miniprep Kit (# K0502) and 
eluting with 30 μL nuclease-free water. Plasmid concentrations were determined using a 
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Thermo Scientific NanoDrop 1000 Spectrophotometer. Plasmid construct DNA 
sequences were verified through sequencing.      
 
Figure 10. General molecular cloning procedure. Target genes are PCR-amplified from 
Ae. aegypti cDNA and digested with restriction enzymes. The expression vector is 
digested with the same restriction enzymes to facilitate ligation of the target gene into the 
expression vector. The vector plasmids are then transformed into E. coli. 
2.1.2 pET28a Plasmid Constructs 
Primers were designed to include the NheI and XhoI restriction sites to enable cloning 
of the gene into the pET28a expression vector (Novagen # 69864-3) in addition to a 
5’-extension to the restriction site (consisting of 5 adenine bases) to increase cleavage 
efficiency of the restriction enzymes.66 Two sets of primers were designed for each target 
protein. The gene fragment obtained was ligated into the bacterial expression vector 
pET28a downstream of the T7 promoter, lac operator, and N-terminal sequence encoding 
six histidine residues (His6-tag) for AaSPII and AaSPIV. Restriction enzymes used in 
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cloning process were Fisher Scientific FastDigest NheI (# FD0973) and XhoI 
(# FD0694). 
The pET28a vector utilizes the inducible T7 expression system in order to express the 
cloned gene sequences in E. coli cells (Figure 11). The T7 RNA polymerase coding 
sequence is present in E. coli cells and is controlled by the lac promoter and induced by 
lactose; the pET28a plasmid is under the control of a promoter recognized by T7 RNA 
polymerase.67 Production of T7 RNA polymerase can be artificially induced by 
isopropyl-β-D-thiogalactoside (IPTG, a non-hydrolyzable analog of allolactose) and 
DNA transcription controlled by the T7 promoter. 
 
Figure 11. Regulation of protein expression with vectors utilizing the T7 expression 
system. Binding of IPTG to the lac repressor induces a conformational change preventing 
the lac repressor from binding to the lac promoter. This allows E. coli RNA polymerase 
to bind and begin transcribing the T7 RNA polymerase. Once T7 RNA is expressed, it 
can bind to the T7 promoter and begin transcribing the gene of interest. Figure adapted by 
author from Novagen pET System Manual. 
 36
2.1.3 Enterokinase (EK)-Pseudo Propeptide Plasmid Constructs 
Since it is unknown whether AaSPII and AaSPIV proteases are autocatalytic or have 
trypsin-like activity, an entrerokinase (EK) cleavage site (DDDDK) was incorporated 
into a pseudo propeptide region introduced via PCR to allow for in vitro activation by 
commercially available recombinant enterokinase (Figure 12).23 The predicted activation 
site was identified by sequence analysis using SignalP 4.1 
(http://www.cbs.dtu.dk/services/SignalP/). Although the sequence analysis suggested that 
the preferred site for activation is at a lysine residue, that site was chosen for design of 
the EK Forward Primer. Primers were designed to include the NheI and XhoI restriction 
sites to enable cloning of the gene into the pET28a expression vector (Novagen) in 
addition to incorporation of the EK cleavage site and 5’-extension to the restriction site 
(5 adenine bases). Restriction enzymes used in cloning process were Fisher Scientific 
FastDigest NheI (# FD0973) and XhoI (# FD0694). The gene fragment obtained was 
ligated into the bacterial expression vector pET28a downstream of the T7 promoter and 
lac operator.  
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Figure 12. Amino acid sequence of the zymogen polypeptide for AaSPII and AaSPIV. 
The protein leader sequence and propeptide region (top) were predicted via sequence 
analyses based on the known sequence of bovine trypsin. Hydrophobic residues of the 
leader sequence and propeptide region are shown in green, negatively-charged residues in 
red, positively-charged residues in blue, and polar uncharged residues in gray. The amino 
acid sequence of the engineered EK-pseudo propeptide forms of the recombinant 
proteases (bottom) is shown. The EK-pseudo propeptide contains an enterokinase 
cleavage site (pink). 
2.1.4 pMAL-c5E Plasmid Constructs 
Additionally, maltose binding fusion protein constructs were designed and cloned 
into the pMAL-c5E vector (NEB # N8110S), which contains the malE gene of E. coli 
that encodes the maltose binding protein (MBP). This E. coli strain lacks the T7 RNA 
polymerase and instead uses the naturally produced E. coli RNA polymerase from the 
bacterial expression cells; expression can still be induced using IPTG. While the exact 
mechanism is unknown, MBP has been shown to act as a highly effective enhancer of 
target protein solubility when used as a fusion protein.47 Escherichia coli MBP is a 
periplasmic protein involved in sugar chemotaxis and transport across the bacterial 
envelope.68 AaSPII (no leader) and full length AaSPIV (with leader) were each cloned 
into the pMAL-c5E vector using each pET28a vector plasmid construct as a template for 
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PCR so that constructs included the His6-tag encoded portion from pET28a constructs for 
later use in purification steps (Figure 13). Primers were designed to contain EcoRI and 
NcoI restriction sites. Restriction enzymes used in the cloning process were Fisher 
Scientific FastDigest EcoRI (# FD0275) and NcoI (# FD0573). The cloned gene was 
inserted downstream the malE gene so that the fusion protein contained MBP 
N-terminally fused to the target protein (with the His6-tag coding sequence from the 
pET28a plasmid construct). 
 
Figure 13. MBP–His6-tag–Protein fusion expected product. To improve soluble 
expression of the target protein of interest, the pMAL-c5E vector was utilized to clone 
the target gene downstream of the Maltose Binding Protein. However, the target gene 
included the N-terminal His6-tag sequence in order to produce the above fusion. 
2.1.5 pET29b Plasmid Constructs 
Additional plasmid constructs using the pET29b vector were developed by students at 
San Jose State University as part of the Fall 2016 Chem 131B lab course using methods 
described here. Primers were designed to include the NcoI and XhoI restriction sites to 
enable cloning of the gene into the pET29b expression vector (Novagen) in addition to a 
5’-extension to the restriction site (5 adenine bases). Unlike the pET28a vector, inserting 
the gene fragment into the pET29b vector incorporates a C-terminal sequence encoding 
six histidine residues (His6-tag) for AaSPII and AaSPIV. Therefore, reverse primers 
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designed did not encode stop codons to allow for incorporation of a C-terminal His6-tag. 
The gene fragment obtained was ligated into the bacterial expression vector pET29b 
downstream of the T7 promoter and lac operator. The pET29b vector also utilizes the 
inducible T7 expression system in order to produce proteins from cloned sequences in 
E. coli cells and production of T7 RNA polymerase can be experimentally induced by 
IPTG (Figure 11). 
2.1.6 Site-Directed Mutagenesis 
Site-directed mutagenesis reactions were used to introduce single base point 
mutations into the known DNA plasmid templates using the Thermo Scientific Phusion 
Site-Directed Mutagenesis Kit (# F541). Two complimentary oligonucleotide primers 
were designed for each reaction to incorporate the desired mutation using guidelines 
described for the Stratagene QuikChange Site-Directed Mutagenesis Kit (# 200518). 
Two sets of mutagenesis primers were designed for different mutations: (1) primers 
for mutating the active site serine residue to an alanine residue and (2) primers for 
mutating the predicted cleavage site residue (lysine) to an alanine residue. Both mutants 
were designed to prevent potential autoactivation of the recombinant enzymes. Reactions 
were prepared by mixing components to a final volume of 50 µL (Table 4). Reactions 
were performed in an Eppendorf 5331 MasterCycler Gradient Thermal Cycler with 
parameters described (Table 5). 
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Table 4. General PCR Reaction for Site-Directed Mutagenesis Reaction – Single Base 
Point Mutation  
Component Quantity 
5X Phusion HF Buffer* 10 µL 
10 mM dNTPs* 1 µL 
10 mM Forward Primer  2.5 µL 
10 mM Reverse Primer 2.5 µL 
1 ng/µL Plasmid Template DNA 1 µL 
2 U/µL Phusion Hot Start DNA Polymerase* 0.5 µL 
Nuclease-Free Water 32.5 µL 
 
Table 5. Thermal Cycler Parameters for Site-Directed Mutagenesis Reaction – Single 
Base Point Mutation  
Steps Cycles Temperature Time 
Initial Denaturation 1 98 °C 30 s 
Denaturation 
25 
98 °C 10 s 
Annealing 65 °C 30 s 
Extension 72 °C 3 min 
Final Extension 1 72 °C 5 min 
Hold 1 20 °C HOLD 
 
All plasmid constructs developed are summarized in Table 6. Plasmid constructs are 
displayed by the assigned annotation, which indicates: the target protein it encodes 
(wild-type AaSPII, wild-type AaSPIV, mutated Ser to Ala AaSPII, or mutated Ser to Ala 
AaSPIV); the plasmid used to facilitate expression; whether the inserted gene sequence 
includes the leader sequence or not; and notable features of each plasmid construct. 
Primers for mutating the predicted cleavage site lysine residue were designed but have 
not yet been cloned into a vector plasmid; mutants listed in the table are those with 
mutations aimed at changing the active site serine residue.  
                                                 
* Included in Thermo Scientific Phusion Site-Directed Mutagenesis Kit (# F541) 
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Table 6. Summary of plasmid constructs developed for expression of recombinant forms of the full length zymogen (with 
leader), mature form (no leader), MBP-fusion, EK-pseudo propeptide, and mutant (Ser to Ala and Lys to Ala) AaSPII and 
AaSPIV. 
Annotation Target Protein Vector Leader Sequence Notable Feature 
AaSPII-pET28a 
WT AaSPII 
pET28a With Leader N-terminal His6-tag 
AaSPII-NL-pET28a pET28a No Leader N-terminal His6-tag 
EK-AaSPII-pET28a pET28a No Leader N-terminal His6-tag and EK cleavage site 
AaSPII-NL-pMAL pMAL-c5E No Leader N-terminal MBP and His6-tag 
AaSPII-NL-pET29b pET29b No Leader C-terminal His6-tag 
AaSPII-NL-Ala-pET28a** Mutant AaSPII  pET28a No Leader N-terminal His6-tag and Mutated Ser to Ala 
AaSPIV-pET28a 
WT AaSPIV 
pET28a With Leader N-terminal His6-tag 
EK-AaSPIV-pET28a pET28a With Leader N-terminal His6-tag and EK cleavage site 
AaSPIV-pMAL pMAL-c5E With Leader N-terminal MBP and His6-tag 
AaSPIV-NL-pET29b pET29b No Leader C-terminal His6-tag 
AaSPIV-Ala-pET28a** Mutant AaSPIV  pET28a With Leader N-terminal His6-tag and Mutated Ser to Ala 
 
                                                 
** Plasmids were constructed for mutation of the active site serine residue to an alanine residue and cloning was successful but 
experiments for the successful recombinant protein expression of the mutant proteases in E. coli have not yet been performed 
and are therefore not discussed in the Results section (Chapter 4).    
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2.2 Recombinant Protein Expression 
SHuffle T7 competent E. coli cells were chosen for bacterial expression of AaSPII 
and AaSPIV because they were engineered to express cytoplasmic proteins containing 
disulfide bonds and are compatible with expression using the T7 promoter system.69 
Plasmid constructs were transformed into SHuffle T7 competent E. coli cells (NEB 
# C3029H) and grown overnight on LB agar with 30 mg/mL kanamycin (the pET28a 
plasmid construct) or 100 μg/mL ampicillin or 50 μg/mL carbenicillin (either antibiotic is 
appropriate for selection of the pMAL-c5E plasmid construct) at 30 ºC. One colony from 
the overnight plate growth was added to 50 mL LB with appropriate antibiotic and grown 
overnight (16−18 h) at 30 ºC with shaking (250 RPM). The optical density at 600 nm 
(OD600) of a ten-fold diluted sample was used to measure culture growth in a Hewlett 
Packard 8452A Diode Array Spectrophotometer and a 1-cm path-length cuvette. 
2.2.1 Induction by IPTG 
Six 1-L Erlenmeyer flasks each containing either 500 mL LB or 500 mL Terrific 
Broth (TB) media with proper antibiotic (based on plasmid antibiotic resistance) and an 
appropriate volume of overnight culture to start at an OD600 of 0.05 was incubated at 
30 ºC with shaking (250 RPM) until reaching OD600 between 0.8 and 1.0. At this time, 
recombinant expression of the target protein (AaSPII or AaSPIV) was induced with 0.1 
M IPTG, the growth temperature dropped to 10 ºC or 15 ºC (250 RPM), and grown for up 
to 96 hours. 1 mL samples were collected at various time-points throughout the growth 
(determined by hours post induction), centrifuged at 13000 RPM for 5 min, and pellets 
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stored at –20 ºC. At the growth experiment endpoint, cell paste was collected by 
centrifugation at 6000 RPM and flash frozen in liquid nitrogen before storage at –80 ºC. 
2.2.2 Auto-Induction 
Methods used for bacterial growth and recombinant protein expression by 
auto-induction was designed with parameters according to the auto-induction process 
outlined by Studier.70 Auto-induction processes use rich media in order to accomplish 
high cell densities, auto-induction (without the use of IPTG), and maximum target protein 
yields.70,71 Studier’s ZYM-5052 auto-induction media, which was also used for this 
study, contains: N-Z-amine (an enzymatic digest of casein), glucose and glycerol to 
support growth to high densities, carbon sources, buffer to maintain pH, critical nitrogen 
and magnesium sources.70 Glucose and lactose are both included in the media: glucose 
prevents induction by lactose in early stages of growth and, once glucose is depleted, 
lactose automatically induces expression of the T7 RNA polymerase.70 Auto-induction 
only works with vectors and bacterial strains containing the T7 expression system, such 
as pET28a, as they require the lacUV5 promoter.67,70,71  
A 125-mL Erlenmeyer flask containing 50 mL Auto-Induction Media (corresponding 
to Studier’s ZYM-5052 medium) with 0.05% w/v lactose, 0.2% w/v glucose, proper 
antibiotic, and an appropriate volume of overnight culture to reach final OD600 of 0.05 
was incubated at 30 ºC with shaking (250 RPM) until reaching OD600 between 0.5 and 
0.8. At this time, the reaction flask was incubated on ice for 5 min and then at 15 ºC with 
shaking (250 RPM) and grown for 72 hours. Bacterial cells were obtained at various 
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time-points throughout the growth by centrifugation of 1 mL samples from growth media 
at 13000 RPM for 5 min and pellets were stored at –20 ºC for further analysis.  
2.2.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Time-points collected throughout the growth were assessed for successful 
recombinant protein expression by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). Sodium dodecyl sulfate (SDS) is an anionic detergent that 
binds to proteins, denaturing them and resulting in a linear structure with a net negative 
charge that is approximately proportional to the protein mass.42 SDS-protein complexes 
can then be subjected to electrophoresis within a polyacrylamide gel and will separate 
based on size: polypeptide chain mobility is inversely linearly proportional to the 
logarithm of their mass so small complexes move more rapidly through the gel.42  
Cells pelleted for each time-point sample were resuspended in 20 mM Tris-HCl 
buffer pH 8. Buffer amount was determined qualitatively based on the size of the largest 
pellet (typically between 250 and 350 µL for growth experiments using induction by 
IPTG and between 600 and 700 µL for growth experiments using auto-induction). 
Samples were maintained on ice and sonicated for 10 s at 20% for a total of three times 
using an ultrasonic probe (Fisher Scientific Model 120 Sonic Dismembrator with 120 
Watt power requirement and 20 kHz operating frequency; QSonica Sonicators converter 
# CL18 and probe # 4423). In new 1.5 mL microcentrifuge tubes, 20 µL from each of the 
total sonicated samples was combined with 3.4 µL 6x SDS Loading Dye. Remaining 
sonicated samples were centrifuged at 13000 RPM for 5 min to pellet in fractions and 
obtain soluble sample fractions. Then, 20 µL from each of the soluble sonicated samples 
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was combined with 3.4 µL 6x SDS Loading Dye. Total and soluble samples with SDS 
Loading Dye added were incubated at 90 °C for 4 min intervals, briefly centrifuging 
between incubation periods until no visible bubbles remained. Samples were 
subsequently loaded into the wells of a NuPAGE Novex 4-12% bis-Tris polyacrylamide 
gel (Thermo Scientific # NP0321BOX, # NP0322BOX, # NP0323BOX) along with 6 µL 
of a protein standard ladder (Thermo Scientific PageRuler Prestained Protein Ladder, 
# 26616). The gel was subjected to electrophoresis in NuPAGE 1x MES SDS Running 
Buffer (Thermo Scientific # NP000202; 50 mM MES, 50 mM Tris Base, 0.1% SDS, 
1 mM EDTA, pH 7.3) at 180 V for 55 min. Following electrophoresis, the gel was rinsed 
three times with approximately 20 mL ultrapure water (purity above 18 MΩ·cm at 25 °C) 
for 5 min. The gel was then stained with 20 mL SimplyBlue SafeStain (Thermo Scientific 
# LC6065) for at least 1 h and then destained with 20 mL ultrapure water for at least 1 h. 
Gels images were obtained using the Alpha Innotech FluorChem 8900 Transillumination 
Imaging System Light Cabinet.  
2.2.4 His-Stain 
To aid in identifying expression of His6-tagged proteins, InVision His6-tag In-gel 
Stain (Novex Life Technologies # LC6030) was also used. The stain contains a dye that 
is conjugated to a Ni2+-nitrilotriacetic acid complex, which binds specifically to the 
six-histidine residues incorporated into the protein of interest. The fluorescent dye can be 
detected using a UV transilluminator. 
Following SDS-PAGE procedures (as previously described), gels were fixed by 
adding 100 mL Fixing Solution (40% v/v ethanol, 10% v/v acetic acid solution), 
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microwaving (~1000 W) for 1 min, and incubating with agitation for 10 min at room 
temperature. The gels were washed by decanting the Fixing Solution and adding 100 mL 
ultrapure water, microwaving for 1 min, and incubating for 5 min with agitation. Then, 
the water was decanted and 25 mL InVision His6-tag In-gel Stain (Novex # LC6030) was 
added, microwaved for 1 min and incubated with agitation for 40 min at room 
temperature. The stain was decanted and gels were then washed by adding 100 mL 
20 mM phosphate buffer, pH 7.8, microwaving for 1 min, and incubating at room 
temperature for 10 min with agitation (three times). Gels were imaged immediately using 
a UV transilluminator, followed by washing with ultrapure water and stained with 
SimplyBlue Safe Stain.    
2.2.5 Western blotting 
The immunoassay technique of Western blotting was used to confirm the successful 
expression of the target recombinant proteins. Western blotting involves detection of 
proteins on the surface of a polymer sheet by exploiting antibody-antigen interactions.42 
A primary antibody specific to the expressed protein is added to the sheet for interaction; 
a secondary antibody labeled with enzyme reporters specific to the primary antibody will 
complex with the primary antibody.42 Light produced by the enzymatic reaction allows 
for detection of the complex; chemiluminescent detection in this manner is extremely 
specific and sensitive. 
In order to verify the presence of the target recombinant protein containing a His6-tag, 
SDS-PAGE was performed as previously described. Following electrophoresis, the gel 
was rinsed three times in approximately 20 mL ultrapure water for 5 min and then rinsed 
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in 20 mL NuPAGE 1x Transfer Buffer (Thermo Scientific # NP0006) with 10% 
methanol for 10–15 min. 
Proteins from the gel were transferred to a nitrocellulose membrane (EMD Millipore 
# ISEQ00010) via electrophoresis with the membrane on the cathode and the gel on the 
anode at 30 V for 1.5 h in NuPAGE 1x Transfer Buffer (Thermo Scientific # NP0006). 
The blot (membrane) was briefly rinsed with water and then rinsed with 10 mL 1x TBS 
(Tris-buffered saline: 20 mM Tris, 137 mM NaCl, pH 7.5) buffer for 5 min. The blot was 
then incubated with Blocking Buffer (3% w/v BSA in 1x TBS with 0.1% Tween 20) at 
room temperature for 1 h with shaking. Three 5 min rinses with 10 mL 1x TBST (1x TBS 
with 0.1% Tween 20) were performed, followed by an overnight incubation at 4 ºC in 
10 mL Primary Antibody Solution prepared by diluting (1:1000) His6-tag Polyclonal 
Antibody (Cell Signaling Technology # 2365) in 3% w/v BSA in 1x TBST. Three 
subsequent 5 min rinses with 10 mL 1x TBST were performed and the membrane was 
then incubated in 10 mL Secondary Antibody Solution prepared by diluting (1:2000) 
secondary antibody (GE Healthcare # NA934-1ML, Amersham enhanced 
chemiluminescent Anti-Rabbit IgG, horseradish peroxidase linked whole antibody from 
donkey) in 3% w/v BSA in 1x TBST for 1 h at room temperature with shaking. Three 
final 5 min rinses with 10 mL 1x TBST were performed before imaging the Western blot. 
The membrane was incubated with SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific # 34077), an enhanced chemiluminescent (ECL) substrate 
for low-picogram-level detection of horseradish peroxidase (HRP), for 1 min and 
visualized in the Alpha Innotech FluorChem 8900 system equipped with a 
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chemiluminescent filter. The image was collected with varying exposure times between 1 
and 10 min. 
2.3 Protein Purification  
2.3.1 Wheat Starch Purification for MBP-Tagged Proteins 
In order to purify MBP-tagged target proteins, a purification method using wheat 
starch was attempted. The binding of MBP to wheat starch is successful due to the 
presence of amylose, which can then be exploited to immobilize the target protein, wash 
away contaminants, and elute the MBP-tagged protein with maltose. Maltose binds with 
stronger affinity to the MBP tag than the wheat starch, facilitating elution of the 
MBP-fusion protein of interest.  
Collected cell paste from previous growth was resuspended in 5 mL/g Resuspension 
Buffer (20 mM Tris-HCl, 250 mM NaCl, pH 7.2). The cell suspension was maintained on 
ice and lysed by sonication at 20% amplitude for a total of 8 min using a pulsing (10 s on, 
15 s off) ultrasonic probe (Fisher Scientific Model 120 Sonic Dismembrator with 120 
Watt power requirement and 20 kHz operating frequency; QSonica Sonicators converter 
# CL18 and probe # 4423). At this point, 20 μL of “total” cell sample was collected. The 
lysed cell solution was centrifuged at 16000 RPM for 30 min at 4 ºC and 20 μL of the 
soluble fraction (crude lysate) was collected.  
Prior to purification, wheat starch is subjected to washing and equilibration. First, 
50 g wheat starch was rinsed three times in water: the wheat starch was suspended in 
200 mL cold ultrapure water and the solution was centrifuged at 12000 RPM for 10 min 
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at 4 ºC. The supernatant was discarded after each rinse. Three additional rinses with 
Resuspension Buffer were then performed.  
After equilibration, 100 mL of the diluted crude lysate solution was added to the 
equilibrated wheat starch and the mixture was incubated at 4 ºC for 30 min with shaking 
(200 RPM). The mixture was centrifuged at 12000 RPM for 6 min at 4 ºC. The 
supernatant (Flow Through 1) was decanted and stored at 4 ºC. The wheat starch was 
then resuspended in 200 mL Resuspension Buffer and centrifuged at 12000 RPM for 
6 min at 4 ºC; collected supernatant was stored at 4 ºC as “Flow Through 2.” Again, the 
wheat starch was resuspended in 200 mL Resuspension Buffer and centrifuged at 
12000 RPM for 6 min at 4 ºC; collected supernatant was stored at 4 ºC as “Flow 
Through 3.” Wheat starch pellet was then resuspended in 50 mL cold Elution Buffer 
(20 mM Tris-HCl, 250 mM NaCl, 25 mM maltose, pH 7.2) and incubated at 4 ºC for 
15 min with shaking (200 RPM). The solution was centrifuged at 12000 RPM for 6 min 
at 4 ºC and the supernatant stored at 4 ºC as “Elution.” The collected elution was again 
centrifuged at 16000 RPM for 10 min at 4 ºC to ensure removal of any remaining wheat 
starch. Total, soluble, flow through, and elution samples were then analyzed via 
SDS-PAGE.  
2.3.2 Fast Protein Liquid Chromatography 
In preparation for purification of the target protein, cell paste was resuspended in 
Buffer A (20 mM Tris-HCl, pH 8); resuspension volume was determined by mass of the 
cell paste (5 mL buffer were used per 1 g cell paste). The solution was then sonicated for 
10 min total (pulse: 10 s on, 15 s off) at 20% amplitude while on ice to lyse cells.  
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Purification of the target protein was performed via Fast Protein Liquid 
Chromatography (FPLC; GE Healthcare AKTA Amersham Pharmica Biotech) using a 
weak anion exchanger column: HiTrap DEAE Sepharose FF 5 mL (GE Healthcare 
# 17-5154-01). Components of the system include: Monitor UPC-900 (GE Healthcare 
# 18-1129-74) for monitoring of UV absorption, pH, and conductivity; Pump P-920 
(Amersham Biosciences # 18-1125-54) high precision laboratory pump; Fraction 
Collector Frac-950 (GE Healthcare # 18608300) for collection in 50 mL polypropylene 
conical tubes (Corning Falcon # 352070) and 96-well DeepWell polypropylene 2 mL 
microplates (Fisher Scientific # 12-566-121); a 10 mL Superloop (GE Healthcare 
# 19-7850-01) for loading sample volumes; and Motor Valve INV 907 for use an 
injection valve (GE Healthcare # 18110840). The procedure was designed and monitored 
using UNICORN Control Software (GE Healthcare). Methods used for purification 
included the following steps: pump wash, column wash, sample loading, and a controlled 
linear gradient elution with Buffer B (20 mM Tris-HCl, 1 M NaCl, pH 8). Following 
completion of the run, the chromatogram was analyzed based on UV detection in order to 
select appropriate fractions to further assess via SDS-PAGE and Western blotting. 
Later purification attempts used alternate columns and buffers; each combination 
used is summarized in Table 7. 
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Table 7. Summary of purification columns and conditions used indicating the type of 
resin, whether anion or cation exchange, and buffers used. 
Column  Type Buffer A Buffer B 
HiTrap DEAE Sepharose FF  
5 mL (# 17-5154-01) 
Weak Anion 
20 mM Tris-HCl, 
pH 8 
Buffer A + 1 M 
NaCl 
HiTrap CM Sepharose FF  
5 mL (# 17-5155-01) 
Weak Cation 
50 mM sodium 
acetate, pH 5.2 
Buffer A + 1 M 
NaCl 
HiTrap SP Sepharose FF  
5 mL (# 17-5157-01) 
Strong Cation 
50 mM acetic acid, 
pH 4.3 
Buffer A + 1 M 
NaCl 
HiTrap DEAE Sepharose FF  
5 mL (# 17-5154-01) 
Weak Anion 
20 mM Tris-HCl, 
1 mM PMSF, pH 8 
20 mM Tris-HCl, 
1 M NaCl pH 8 
 
2.4 Qualitative Activity Assay 
In order to detect trypsin-like activity in purified fractions, which would suggest that 
the recombinant enzymes are active, the synthetic colorimetric substrate for trypsin 
BApNA was used. Upon cleavage of BApNA by enzymes with trypsin-like activity, a 
yellow product (p-nitroaniline) is generated with color intensity proportional to enzyme 
concentration.60 While BApNA can be used as a substrate to obtain kinetic constants once 
a protein is successfully purified, for this work, it was used qualitatively to determine 
whether or not activity was present in purified fractions.   
Each reaction was prepared in a 1.5 mL microcentrifuge tube and contained 20 mM 
Tris-HCl, pH 7.2, 10 mM CaCl2, 1 mM BApNA, and ultrapure water for a total volume 
of 990 µL. For each reaction, 10 µL from the sample fraction in question was added and 
the solution vortexed to mix and incubated at room temperature overnight. Reaction 
mixtures were observed to assess the color intensity of solutions that showed a yellow 
color following incubation to determine if any samples were positive for trypsin-like 
activity. 
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CHAPTER 3: RESULTS AND DISCUSSION 
3.1 Molecular Cloning 
As described in the previous section, PCR amplification (Figure 14) and vector 
digestion (Figure 15) steps in the cloning process were qualitatively assessed via agarose 
gel electrophoresis.  
 
Figure 14. 1% Agarose gel of AaSPIV PCR products using primers designed for cloning 
into the pET28a vector. Lanes 1 and 2 are duplicate PCR reactions at 58 ºC and lane 3 is 
the DNA Ladder in base pairs (Thermo Scientific GeneRuler 1 kb DNA ladder). The 
expected PCR product is 885 bp (indicated by the arrow). 
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Figure 15. 1% Agarose gel of digested and dephosphorylated pET28a vector. Lane 1 is 
the DNA Ladder in base pairs (Thermo Scientific GeneRuler 1 kb DNA ladder). Lane 2 
contains the digested and dephosphorylated pET28a vector at 5296 bp (indicated by the 
arrow). 
Following confirmation of successful PCR and vector digestion (Figures 14 and 15), the 
digested and dephosphorylated vector was combined with the PCR product, ligated, and 
transformed into bacterial cells. Successful cloning was assessed via colony PCR (Figure 
16). The AaSPII/pET28a and AaSPIV/pET28a plasmid constructs were then isolated 
from the bacterial cells and sequenced to confirm successful molecular cloning.  
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Figure 16. 1% Agarose gel of Colony PCR reactions showing positive hits of the 
AaSPIV gene. Colony PCR was used to verify successful molecular cloning of the 
AaSPIV-pET28a plasmid construct. Lane 9 is the DNA Ladder in base pairs (Thermo 
Scientific GeneRuler 1 kb DNA ladder). Lanes 1, 2, 3, 5, 6, and 8 showed a PCR product 
in the expected region (885 bp). 
Cloning of all constructs of AaSPII and AaSPIV, whether it was for full-length 
recombinant proteases, proteases without the leader sequence, incorporation of the 
EK-pseudo propeptide or the MBP-fusion tag, was performed as described in the 
methods (see Table 6). All constructs were confirmed by sequencing (data not shown).   
Sequencing results obtained for the AaSPIV-pET28a plasmid constructs revealed a 
change at two specific nucleotides not found in the original AaSPIV gene sequence 
annotated in the National Center for Biotechnology Information (NCBI) website.35 The 
first nucleotide change led to an amino acid change at position 162 (lysine) to a glutamate 
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residue. The second nucleotide that did not match the annotated sequence resulted in an 
arginine residue at position 288 (instead of a lysine residue).35 Initially, these two 
nucleotide changes were thought to be mutations introduced during the cloning process, 
especially since Ae. aegypti cDNA was used as the template. However, these changes 
were observed consistently even after multiple cloning attempts were performed, 
indicating the possibility that the published Ae. aegypti gene sequence for AaSPIV was 
incorrectly annotated, which has been known to occur.72-76 Most cases of misannotation 
are associated with overprediction of molecular function.76 Additional problems 
associated with genome annotation include: expressed sequence tags (ESTs; short mRNA 
sequences derived from cDNA libraries) are susceptible to artifacts, repetitive elements in 
cDNA can cause false homology matches, similarities between species do not often take 
into account evolutionary divergence or homologs, and alignments can be severely 
complicated by alternative splicing.77 To ensure that this was the case, a fresh new batch 
of Ae. aegypti cDNA was prepared (by Dr. Jun Isoe, University of Arizona) and the 
cloning was repeated by Mr. Bryan Tracy Conner (an undergraduate research student in 
the Rascón lab). His experiments resulted in the same amino acid changes observed in the 
original AaSPIV-pET28a constructs.  
It is also well established that high genetic variability between different Ae. aegypti 
strains or between populations in different geographic regions exists, which may also 
account for the two observed nucleotide discrepancies.78-80 Potential variation of these 
two amino acid residues between Ae. aegypti strains may indicate that the residues are 
not highly conserved suggesting that the properties of these specific amino acid residues 
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may not be essential for folding or function.42 Often, features of the protein structure 
necessary for structure and/or function can depend on general properties associated with 
tertiary structure as opposed to conserved protein sequences; these can include exposure 
of surface polar or charged residues, which can exchange protons with water.42,81,82 
Because the amino acids in question were annotated at lysine residues 
(positively-charged) and the amino acids discovered in plasmid constructs were a 
glutamate residue (negatively-charged) and an arginine residue (positively-charged) it is 
possible that residues at these positions only need to be charged—and perhaps the amino 
acid at position 288 needs to specifically be positively-charged—for proper structure and 
function of the native AaSPIV protease.           
3.2 Recombinant Protein Expression 
Growth experiments were performed to determine the optimal conditions for 
maximizing soluble recombinant expression of both AaSPII and AaSPIV. As such, 
multiple approaches were taken initially to compare various effects on bacterial growth 
and recombinant protein expression. This included using different types of media, growth 
temperature, induction by IPTG or auto-induction, incorporation of fusion tags like MBP 
or a His6-tag, and replacing the propeptide region with an EK-pseudo propeptide.  
Initially, growth experiments were conducted with pET28a plasmid constructs to 
yield N-terminally His6-tagged recombinant enzymes (AaSPII without leader, AaSPIV 
with leader) using SHuffle T7 E. coli cells grown at 10 ºC for a total of 64 h in either LB 
media (results not shown) or TB media (See Figures 17 and 18). Effects of recombinant 
target protein expression using LB and TB media were assessed but expression with TB 
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media was clearly superior (higher expression levels of total recombinant proteases). TB 
media (12 g/L tryptone, 24 g/L yeast extract, 9.4 g/L K2HPO4, 2.2 g/L KH2PO4, and 
0.4% v/v glycerol) is much richer than LB media (10 g/L tryptone, 5 g/L yeast extract, 
and 5 g/L NaCl) and provides more effective buffering against metabolic pH changes due 
to the inclusion of monobasic and dibasic potassium phosphate.83 For this reason, growth 
experiments using LB media can limit target protein expression due to acid produced via 
glucose metabolism surpassing buffering capabilities of LB media and halting cell 
growth and protein synthesis.83 
Lowering the temperature has been shown to reduce protein aggregation in 
difficult-to-express proteins, but at the same time slows bacterial growth and metabolism, 
and so to further increase soluble expression, growth times were extended when lower 
temperatures used.47 Factors contributing to increased solubility of recombinant proteins 
at reduced expression temperatures include the temperature-dependence of hydrophobic 
interactions that can lead to protein aggregation and the prevention of bacterial heat 
shock protein expression that could otherwise be induced in recombinant overexpression 
conditions.47 Additionally, lower temperatures slow the bacterial protein expression 
machinery, leading to lower expression rates of proteins and thus more chaperone 
proteins are available to aid in proper folding (despite optimal chaperone activity and 
expression ~30 ºC).47,83    
Another factor that is typically problematic in recombinant protein expression is the 
presence of disulfide bonds in the target protein required for proper folding and 
solubility; both AaSPII and AaSPIV are predicted to form four disulfide bonds in the 
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native conformation, which may not be properly forming during growth 
experiments.47,49,84 Because correctly forming the native disulfide bonds between these 
eight cysteine residues (of 105 possible isomers) is essential to proper folding, SHuffle 
T7 competent E. coli cells were chosen for expression in anticipation of potential 
expression difficulties associated with improper folding of disulfide-bonded proteins 
because they express the disulfide bond isomerase DsbC, which acts as a chaperone to 
aid in protein folding and the correction of mismatched disulfide bonds.47,49,69,84 The 
strain also contains deletions of the genes for glutaredoxin reductase and thioredoxin 
reductase leading to a more oxidizing cytoplasm and facilitating proper disulfide bond 
formation.49,50,69  
As shown in Figures 17 and 18, the recombinant enzymes (AaSPII without leader and 
AaSPIV with leader) were successfully expressed, but as in insoluble proteins. They were 
only found in the total samples, which represent all of the total proteins and enzymes 
expressed by the bacterial cells, including the recombinant enzyme of interest.85 No 
visible bands corresponding to the enzymes of interest are observed in the soluble 
samples. This may be due to misfolding of the target enzymes, which is a common 
occurrence for disulfide-bonded proteins and would result as insoluble aggregated 
proteins known as inclusion bodies.47 Unfavorable protein-folding conditions caused by 
macromolecular crowding can lead to the formation of inclusion bodies, which occurs as 
a response to stress caused by high rates of recombinant protein expression.86  
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Figure 17. 4-12% BIS-TRIS Gel analysis of samples collected from a 64 h growth experiment of AaSPII-NL-pET28a in 
SHuffle T7 E. coli cells grown at 10 ºC using TB media. Lane 1 is the protein Molecular Weight (MW) ladder (Thermo 
Scientific PageRuler (in kDa). From left to right, lanes include total and soluble samples at various time-points (labeled by h). 
Total samples show target protein expression at the expected MW region (~32 kDa). 
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Figure 18. 4-12% BIS-TRIS Gel analysis of samples collected from a 64 h growth experiment of AaSPIV-pET28a in SHuffle 
T7 E. coli cells grown at 10 ºC using TB media. Lanes 1 and 8 are the protein Molecular Weight (MW) ladder (Thermo 
Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points (labeled 
by h). Total samples show target protein expression at the expected MW region (~32 kDa). 
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Additionally, the metabolic burden of recombinant protein expression imparted on 
bacterial cells often limits cell growth; growth rates of bacterial cells containing vector 
plasmids suffer due to the added strain of plasmid replication and cellular translation and 
transcription mechanisms.85,87,88 Therefore, expression via auto-induction was pursued in 
an attempt to increase soluble protease expression; because auto-induction techniques 
enable bacterial cells to grow to high density before expression is induced, higher total 
target protein expression levels can be achieved by limiting the metabolic stress bacterial 
cells can undergo during recombinant protein expression.70,71 To determine if this would 
be the case for AaSPII (no leader) and AaSPIV (with leader), both enzymes were 
expressed under auto-induction conditions (auto-induction media) in SHuffle T7 E. coli 
cells at 10 ºC for a total of 96 h (Figures 19 and 20). 
Unfortunately, soluble expression of AaSPII (no leader) and AaSPIV (with leader) 
using SHuffle T7 cells and auto-induction media (Figures 19 and 20) showed no visible 
bands in the expected region associated with the size of target proteins. Both were found 
only in the total samples. Additionally, these bands appeared to be less intense (lower 
expression) than those associated with expression using TB media and IPTG induction 
(Figures 17 and 18). However, initial comparison of the expression of these recombinant 
enzymes in TB and in auto-induction media is somewhat misleading: while the 
expression level of target protein (based on band intensity) was higher for IPTG-induced 
growth samples, the overall yield of all expressed proteins was lower. Because 
auto-induced cultures grew to notably higher cell densities, the overall yield of all 
expressed proteins was much higher for auto-induced growth samples.70 Because 
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recombinant protein expression is suppressed in the auto-induction process until glucose 
and glycerol in the media are depleted, cells can grow to high densities without suffering 
metabolic stress before recombinant protein production begins. 70Additionally, the rich 
auto-induction media (1% N-Z-amine, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM 
KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.5% glycerol, 0.05% glucose, 
and 0.2% lactose) is designed for higher availability of bacterial nutrient sources as well 
as better pH regulation for optimal bacterial cell growth until nutrient sources are 
depleted and protein expression is auto-induced by lactose present in the media.70 
Although growth experiments under auto-inducing conditions did not seem to promote 
soluble protein expression as hoped, increased yields of insoluble target proteins would 
be an improvement if later refolding methods are used.47,89 Because refolding techniques 
are consistently inefficient, higher initial protein yields would maximize final yields.47,89     
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Figure 19. 4-12% BIS-TRIS Gel analysis of samples collected from a 96 h growth experiment of AaSPII-NL-pET28a in 
SHuffle T7 E. coli cells grown at 10 ºC using auto-induction. Lane 1 is the protein Molecular Weight (MW) ladder (Thermo 
Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points (labeled 
by h). Total samples show target protein expression at the expected MW region (~32 kDa). 
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Figure 20. 4-12% BIS-TRIS Gel analysis of samples collected from a 96 h growth experiment of AaSPIV-pET28a in SHuffle 
T7 E. coli cells grown at 10 ºC using auto-induction. Lanes 1 and 8 are the protein Molecular Weight (MW) ladder (Thermo 
Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points (labeled 
by h). Total samples show target protein expression at the expected MW region (~32 kDa)
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Since the described attempts at expressing soluble recombinant AaSPII and AaSPIV 
(media, temperature, and bacterial cells) failed, the decision was made to determine if 
modifying the natural propeptide region with an EK-pseudo propeptide region would aid 
in the soluble expression of AaSPII by preventing possible autoactivation of the 
recombinant enzymes, but also in removing eukaryotic nucleotides rarely found in E. 
coli.23,90,91 When foreign mRNA contains excessive codons that are rare in E. coli, less 
abundant tRNAs can be depleted, leading to incorporation of the wrong amino acid or 
truncation, both of which cause decreased target protein expression levels. The 
EK-pseudo propeptide plasmid construct was expressed in SHuffle T7 E. coli cells grown 
under two different sets of conditions: (1) auto-induced and grown in auto-induction 
media at 30 ºC for 24 h (Figure 21) or (2) induced by IPTG and grown in TB media at 
15 ºC for 72 h (Figure 22). 
It has been proposed that the lack of an enterokinase cleavage site in the zymogen 
form of Ae. aegypti trypsin-like serine proteases homologous to mammalian trypsinogen 
is indicative of autocatalytic behavior; but, this has not yet been shown definitively.44 
Additionally, other abundant Ae. aegypti serine proteases of study in the Rascón lab have 
been shown to be autocatalytic (results not published). Incorporation of the EK-pseudo 
propeptide region at the N-terminus of express recombinant target proteins was 
performed for two main purposes: (1) to overcome potential autoactivation of 
recombinant AaSPII or AaSPIV proteases in addition to autodigestion and thus contribute 
to difficulties in obtaining soluble expression and (2) to facilitate in vitro activation post 
purification.23   
 66
 
 
Figure 21. 4-12% BIS-TRIS Gel analysis of samples collected from a 24 h growth experiment of EK-AaSPII-pET28a in 
SHuffle T7 E. coli cells grown at 30 ºC using auto-induction. Lanes 1 and 8 are the protein Molecular Weight (MW) ladder 
(Thermo Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points 
(labeled by h). Total and soluble samples show target protein expression at the expected MW region (~32 kDa).  
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Figure 22. 4-12% BIS-TRIS Gel analysis of samples collected from a 72 h growth experiment of EK-AaSPII-pET28a in 
SHuffle T7 E. coli cells grown at 15 ºC using auto-induction. Lane 1 is the protein Molecular Weight (MW) ladder (Thermo 
Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points (labeled 
by h). Total samples show target protein expression at the expected MW region (~32 kDa).
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SDS-PAGE results from the two growth experiments (Figure 21, Figure 22) to 
express the EK-pseudo propeptide plasmid construct did not show high expression levels 
in either total or soluble samples. However, soluble expression of AaSPII with the 
EK-pseudo propeptide at 30 ºC using auto-induction media (Figure 21) was observed in 
the predicted region of the gel (~32 kDa). Since growth under 30 ºC auto-induction 
conditions showed some soluble target protein expression (Figures 21 and 23), the 
growth experiment was repeated but, rather than grow at 30 ºC only, the temperature was 
lowered to 15 ºC after reaching an OD600 of approximately 0.8 in an effort to increase 
soluble expression; unfortunately, there was no visible expression in SDS-PAGE or 
Western blot analyses of later growth experiments using auto-induction methods 
performed at 15 ºC (results not shown). Because the growth temperature was lowered in 
an attempt to increase soluble expression, a loss of soluble expression at lower 
temperatures (Figure 20) was unexpected. However, this may be due to bacterial protein 
chaperone activity and expression, which is typically optimal in E. coli at 30 ºC.47 While 
heat shock proteins can function as chaperones at high temperatures, cold shock proteins 
typically function as RNA chaperones at low temperatures.92,93 Additionally, beneficial 
effects of low growth temperatures can become overwhelmed by the lowered 
transcription and translation efficiency of E. coli. 92,93 
  In order to determine if low levels of soluble AaSPII with the EK-pseudo propeptide 
(Figure 20) were expressed at 30 ºC using auto-induction techniques and confirm if bands 
associated with total samples in the appropriate molecular weight region could indeed be 
attributed to target protein expression, analysis of growth experiment time-points by 
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Western blot was performed (Figure 23). Because Western blotting uses antibody-antigen 
interactions to visualize expression of the target protein, it is a much more specific and 
sensitive technique (compared to visualization by SDS-PAGE, which is not specific for a 
particular protein); eliminating visualization of non-specific background bacterial protein 
expression would increase confidence in confirming expression of the target protein.42 
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Figure 23. Western blot analysis of samples collected from a 24 h growth experiment of EK-AaSPII-pET28a in SHuffle T7 E. 
coli cells grown at 30 ºC using auto-induction. Lane 1 is the protein Molecular Weight (MW) ladder (Thermo Scientific 
PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points (labeled by h). Total 
and soluble samples show target protein expression at the expected MW region (~32 kDa). 
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As shown in Figure 23, Western blot analysis revealed successful expression of the 
His6-tagged protein at low levels in both total and soluble fractions. In the later 
time-point samples (taken at 18 and 24 h), there are also bands present in lower molecular 
weight regions. This may indicate that, despite incorporation of the EK-pseudo 
propeptide region, the expressed proteins have autoactivated and begun autodigesting, 
resulting in the presence of smaller molecular weight peptides containing the His6-tag. If 
this is the case for AaSPII and AaSPIV, despite incorporation of the EK-pseudo 
propeptide, it may be due to the presence of the lysine residue at the cleavage site, which 
is also present in the wild-type protease; if autoactivation of the proteases is facilitated by 
the presence of the lysine residue (which is consistent with trypsin substrate specificity), 
incorporation of the EK cleavage site (DDDDK) would not prevent autoactivation.94 
Aside from the amino sequence of the propeptide region, one factor that can contribute to 
autoactivation of mammalian trypsinogen includes modification of the protein surface 
charge since autoactivation is promoted by protein-protein interactions.95  
Additionally, comparison of the SDS-PAGE results (Figure 21) with the 
complementary Western blot (Figure 23) for expression of AaSPII containing the EK-
psuedo propeptide region in SHuffle T7 E. coli cells grown at 30 ºC under auto-induction 
conditions shows that, despite achieving soluble expression, the expression level (band 
intensity) of the target protein is similar to expression levels of bacterial proteins. 
Because target protein yields were relatively minimal, the AaSPII (no leader) and 
full-length AaSPIV (with leader) genes were each cloned into the pMAL-c5E vector for 
expression of the protein using the pET28a plasmid constructs as templates. Expressing 
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recombinant enzymes as MBP-tagged proteins has been shown dramatically increase the 
expression levels of soluble recombinant proteins and use of this method was performed 
in hopes of achieving similar results for AaSPII (no leader) and full length AaSPIV (with 
leader).47 Using the pET28a plasmid constructs as templates for insertion allowed for 
incorporation of the His6-tag between the N-terminal MBP and C-terminal recombinant 
enzyme (Figure 13); incorporation of the His6-tag should not interfere with expression.96 
Additionally, the use of MBP and the His6-tag provide two potential downstream 
methods of purification (exploitation of MBP-amylose binding or of metal affinity to the 
His6-tag); optimal purification methods for obtaining the higher purified protein yields 
can be determined by using one or both of the two methods.96 In many previous 
instances, MBP for high soluble expression levels in combination with the robust method 
IMAC method of purification has been shown to be very effective for difficult-to-express 
proteins.96  
MBP-tagged AaSPII without the leader sequence (MBP-AaSPII) and MBP-tagged 
full length AaSPIV with the leader sequence (MBP-AaSPIV) were expressed in LB 
media at 15 ºC for 24 h (MBP-AaSPII; Figure 24) or for 48 h (MBP-AaSPIV; Figure 25). 
Additionally, to determine if soluble expression could be increased by altering growth 
time, temperature, and media, the growth experiment to express MBP-AaSPIV was 
repeated using the AaSPIV-pMAL plasmid construct in SHuffle T7 cells grown in TB 
media at 12 ºC for 77 h; results were assessed via His-Stain procedure to reduce 
visualization of background protein expression in the gel (Figure 26).  
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Figure 24. 4-12% BIS-TRIS Gel analysis of samples collected from a 24 h growth experiment of AaSPII-pMAL-c5E in 
SHuffle T7 E. coli cells grown at 15 ºC using LB media. Lanes 1 and 7 are the protein Molecular Weight (MW) ladder 
(Thermo Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points 
(labeled by h). Total and soluble samples show target protein expression at the expected MW region (~75 kDa). 
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Figure 25. 4-12% BIS-TRIS Gel analysis of samples collected from a 48 h growth experiment of AaSPIV-pMAL-c5E in 
SHuffle T7 E. coli cells grown at 15 ºC using LB media. Lanes 1 and 8 are the protein Molecular Weight (MW) ladder 
(Thermo Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble samples at various time-points 
(labeled by h). Total and soluble samples show target protein expression at the expected MW region (~75 kDa). 
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Figure 26. 4-12% BIS-TRIS Gel analysis of soluble samples collected from a 77 h growth experiment of AaSPIV-pMAL-c5E 
in SHuffle T7 E. coli cells grown at 12 ºC using TB media. Lane 1 is the protein Molecular Weight (MW) ladder (Thermo 
Scientific PageRuler, in kDa). From left to right, other lanes include soluble samples at various time-points (labeled by h). 
Samples show target protein expression at the expected MW region (~75 kDa).
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As expected, growth experiments with MBP-tagged recombinant enzymes (Figures 
24, 25, and 26) significantly increased expression levels in both total and soluble 
samples. Results showed that expression of pMAL-c5E plasmid constructs in SHuffle T7 
cells grown at 15 ºC in LB media (Figures 24 and 25) resulted in similar expression of 
MBP-AaSPII and MBP-AaSPIV as compared to growth in TB media (results not shown). 
Expression with the MBP-fusion tag using LB media seemed to be sufficient; potential 
buffering problems with LB that could lead to poor soluble target protein yield were 
counterbalanced by the improved expression due to the MBP-fusion tag while expression 
of background bacterial proteins was limited, which could aid in downstream purification 
processes, and so LB media was used to express MBP-AaSPII or MBP-AaSPIV in later 
growths.83 
Extending growth times also did not seem to significantly increase soluble protein 
expression; expression of pMAL-c5E plasmid constructs in SHuffle T7 E. coli cells at 
15 ºC in LB media for 24 h (MBP-AaSPII; Figure 24) or for 48 h (MBP-AaSPIV; Figure 
25) were sufficient to maximize soluble target protein yields as predicted, due to the 
robustness of the MBP-fusion tag for use as a solubility enhancer.47,96  
3.3 Initial Purification Attempts and Qualitative Activity Assay 
For both enzymes (AaSPII without the leader sequence and AaSPIV with the leader 
sequence), expression using the MBP-fusion tag (pMAL-c5E plasmid constructs) resulted 
in soluble recombinant protein expression; and so, this method was used for large-scale 
protein expression for purification. As mentioned, one benefit of using the pMAL-c5E 
plasmid constructs is that we were able to clone the genes with the N-terminal His6-tag in 
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place, thereby creating the MBP-fusion protein (Figure 13), both of which can be 
exploited in the purification process.96 Initial purification attempts of MBP-AaSPIV (with 
leader) were performed using the wheat starch purification protocol previously outlined. 
Unfortunately, SDS-PAGE analysis of fractions obtained throughout the purification 
process indicated purification was unsuccessful (Figure 27). SDS-PAGE results show a 
visible band of appropriate size and intensity associated with the total sample; however, 
the band is no longer visible in the soluble sample or in any of the later flow through or 
elution samples (see Figure 27).  
 
Figure 27. 4-12% BIS-TRIS Gel analysis of fractions collected from wheat starch 
purification of MBP-AaSPIV recombinant protease expressed in SHuffle T7 cells grown 
at 15 ºC for 48 h in LB media. Lane 1 is the protein Molecular Weight (MW) ladder 
(Thermo Scientific PageRuler, in kDa). From left to right, other lanes include total and 
soluble samples three subsequent flow through samples (FT 1, FT 2, and FT3), and the 
elution sample. Only the total sample shows target protein expression at the expected 
MW region (~75 kDa). 
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The observed absence of MBP-AaSPIV in the soluble fractions (Figure 27), despite 
evident soluble expression in the large-scale growth (Figure 25), suggests that the 
MBP-fusion proteases may be autoactivating.44 Interestingly, results of the His-Stain 
procedure used to visualize expression of the His6-tagged MBP-AaSPIV recombinant 
fusion protein revealed potential autoactivation at low levels due to the presence of a 
protein species at around 50 kDa (Figure 26). From the His-Stained gel, high levels of 
soluble expression are observed at the expected molecular weight of ~75 kDa, but upon 
careful analysis, the presence of faint bands at the lower molecular weight (~50 kDa) 
becomes evident. The major reason visualization by His-Stain is used is because this stain 
eliminates bands associated with background bacterial protein expression, especially 
those that lack the His6-tag, therefore making it easier to distinguish between native 
bacterial proteins and the target His6-tagged recombinant enzymes.  
 Autoactivation leading to cleavage at the predicted cleavage site would result in free, 
active soluble recombinant AaSPIV (MW ~28 kDa) and free His6-tagged MBP (MW ~47 
kDa) (see scheme in Figure 28) (combined MW of the fusion protein ~75 kDa), 
effectively preventing purification of the target enzyme using wheat starch, which has a 
fair amount of amylose. As mentioned, MBP will naturally bind to amylose, and it is 
expected that free MBP should be visible in the elution fraction after the addition of 
maltose. However, there is nothing visible in the elution sample (Figure 27), which may 
support the autoactivation of AaSPIV, in which this active protease is cleaving and 
digesting the His6-tagged MBP.44 
 79
 
Figure 28. Scheme showing cleavage of the MBP–His6-tag–Protein fusion product 
following autoactivation, resulting in free His6-tagged MBP and free active target protein. 
Initial failed attempts using the wheat starch batch purification method prompted 
purification trials using ion exchange chromatography to remove contaminants and purify 
based on the pI of the MBP-fusion protease. Typically, multiple purification steps are 
performed in succession to recover pure target proteins; in these cases, inclusion of the 
MBP (which can bind to wheat starch and amylose resin) and the His6-tag (recoverable 
via IMAC) presents possibilities for future purification steps in addition to other options 
such as size-exclusion chromatography.96 However, since the initial wheat starch method 
was unsuccessful, ion exchange was attempted using the following specifications: 
MBP-AaSPII and MBP-AaSPIV expressed in SHuffle T7 cells grown at 15 ºC for 48 h in 
LB media purified via FPLC using a DEAE (weak) anion exchange column in 20 mM 
Tris-HCl, pH 8 buffer (Figures 29 and 30). 
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Figure 29. 4-12% BIS-TRIS Gel analysis of fractions collected from purification via FPLC using DEAE anion exchange 
column in 20 mM Tris-HCl, pH 8 buffer of MBP-AaSPII recombinant protease expressed in SHuffle T7 cells grown at 15 ºC 
for 48 h in LB media. Lanes 1 and 21 are the protein Molecular Weight (MW) ladder (Thermo Scientific PageRuler, in kDa). 
From left to right, other lanes include total and soluble samples, two subsequent flow through samples (FT 1 and FT 2), and 
elution samples labeled according to the corresponding location in the 96-well collection microplate. Only the total sample 
shows target protein expression at the expected MW region (~75 kDa). 
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Figure 30. 4-12% BIS-TRIS Gel analysis of fractions collected from purification via FPLC using DEAE anion exchange 
column in 20 mM Tris-HCl, pH 8 buffer of MBP-AaSPIV recombinant protease expressed in SHuffle T7 cells grown at 15 ºC 
for 48 h in LB media. Lanes 1 and 23 are the protein Molecular Weight (MW) ladder (Thermo Scientific PageRuler, in kDa). 
From left to right, other lanes include total and soluble samples, two subsequent flow through samples (FT 1 and FT 2), and 
elution samples labeled according to the corresponding location in the 96-well collection microplate. Only the total sample 
shows target protein expression at the expected MW region (~75 kDa).
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Initial results from the anion exchange purification of MBP-AaSPII and 
MBP-AaSPIV recombinant enzymes (Figures 29 and 30) were similar to those observed 
using the wheat starch purification method (Figure 27): a band of the correct size and 
intensity (~75 kDa) is visible in the total sample (indicative of the MBP-fusion target 
enzyme), but not present in the soluble sample or in later fractions taken throughout the 
flow through or elution process. This outcome, in combination with corresponding 
previous results of wheat starch purification methods, provides consistent evidence in 
support of the potential autocatalytic behavior of AaSPII and AaSPIV.44 In an attempt to 
confirm if autoactivation and/or autodigestion of the recombinant enzymes is indeed 
occurring, analysis of FPLC fractions by Western blotting was performed to locate any 
cleaved His6-tagged peptides in the fractions (Figure 31).
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Figure 31. Western blot analysis of fractions obtained from purification attempt via FPLC using DEAE anion exchange 
column in 20 mM Tris-HCl, pH 8 buffer of MBP-AaSPIV expressed in SHuffle T7 cells grown at 15 ºC for 48 h in LB media. 
Lane 1 is the protein Molecular Weight (MW) ladder (Thermo Scientific PageRuler, in kDa). From left to right following the 
ladder, lanes include total and soluble samples, two subsequent flow through samples (FT 1 and FT 2), and elution samples 
labeled according to the corresponding location in the 96-well collection microplate. Total, soluble, and fractions B8, B12, and 
C4 show His6-tagged protein expression at a much lower MW region than expected (~50 kDa observed, ~75 kDa expected).  
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Results of the Western blot (Figure 31) from collected purified fractions of 
MBP-AaSPIV using DEAE clearly show a protein species with a His6-tag in the soluble 
sample and in later elution fractions at a much lower molecular weight than anticipated 
(~50 kDa observed, rather than the ~75 kDa that is expected). This provided further 
evidence that the enzyme is autocatalyzing at the propeptide cleavage region resulting in 
the loss of the His6-tag on the target protease, but cleaving the site to remain on the MBP 
(Figure 28). This initial hypothesis is based on amino acid sequence analysis suggesting 
the likely location of protein cleavage leading to autoactivation: two protein species 
would potentially be produced: MBP with the His6-tag and propeptide region of the 
enzyme (~47 kDa) and the active, recombinant enzyme (~28 kDa for both AaSPII and 
AaSPIV). The only probable conclusion that can be made is that autoactivation is 
occurring during the purification process, leading to free, activated AaSPIV recombinant 
enzyme (as shown in the scheme depicted in Figure 28) and the MBP with the His6-tag 
on the C-terminus.44 Overlaying the results of the Western blot (Figure 31) with those of 
the complementary SDS-PAGE (Figure 30) shows very clearly in which purification 
fractions the cleaved His6-tagged protein appears and at what approximate concentrations 
based on band intensity (Figure 32).  
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Figure 32. Overlay of Western blot (Figure 31) and complementary SDS-PAGE (Figure 
30) performed on fractions obtained from purification attempt via FPLC using DEAE 
anion exchange column in 20 mM Tris-HCl, pH 8 buffer of AaSPIV-pMAL expressed in 
SHuffle T7 cells grown at 15 ºC for 48 h in LB media. 
The results observed from the wheat starch and anion exchange purification is not at 
all too surprising since mammalian trypsins have been shown to autoactivate at slightly 
alkaline conditions (pH ~7–9) and can digest other proteins in the cytosol once active.46 
In addition, AaSPII and AaSPIV, as well as other Ae. aegypti serine proteases, lack the 
enterokinase cleavage site present in mammalian trypsins (the main autocatalytic 
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regulation mechanism) indicating that autoactivation is the likely mechanism responsible 
for activation of these digestive mosquito enzymes.22,36,44,46,61 Thus far, the Rascón lab 
has successfully determined that the most abundant midgut proteases are indeed 
autocatalytic (unpublished results).   
While autoactivation of the MBP-fusion recombinant proteases presents extensive 
purification challenges, it indicates that the recombinant target enzymes are properly 
folded and active. Thus, based on these results, we can confidently suggest that 
successful soluble expression was achieved and the native disulfide bonds found in 
AaSPII and AaSPIV were successfully formed in the folding process. While it also seems 
reasonable to expect that the bulky MBP-fusion tag might inhibit autoactivation (which 
depends on successful protein-protein contacts) and any subsequent enzyme activity, this 
was surprisingly not the case. However, previous literature does implicate that other 
enzymes expressed with an MBP-fusion tag have also been shown to retain activity 
comparable to the free, active enzyme and were not inhibited by the presence of the 
MBP-fusion protein.95,97-99 In order to confirm the presence of trypsin activity in any of 
the fractions and to determine which fractions might contain the target proteases, a 
qualitative enzyme activity assay using the chromogenic trypsin peptide substrate analog 
BApNA was performed on each DEAE purified fraction, as described in the Methods 
section. As shown in Figure 33, the soluble fraction and later elution fractions 
(corresponding to C6–D5, Figure 30) were positive for trypsin activity (yellow). 
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Figure 33. Qualitative enzyme activity assay reaction samples using BApNA to detect the presence of trypsin-like activity in 
fractions collected from purification via FPLC using DEAE anion exchange column in 20 mM Tris-HCl, pH 8 buffer of 
AaSPIV-pMAL expressed in SHuffle T7 cells grown at 15 ºC for 48 h in LB media. From left to right and top to bottom, 
reaction samples are the soluble fraction and elution samples labeled according to the corresponding location in the 96-well 
collection microplate. A yellow color indicative of trypsin-like activity is visible in the soluble sample and in reaction tubes 
labeled C6, C8, C11, D2, and D5. 
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While no negative control is shown here, similar assays have been performed by 
members of the Rascón lab using total and soluble bacterial protein samples without 
expression of the recombinant serine proteases resulting in no color change or indication 
of trypsin activity. Confirmation of trypsin activity in purification fractions seems 
promising but also indicates further challenges associated with obtaining purified 
enzyme. Specifically, cleavage at the predicted cleavage site results in free, active 
enzyme without the His6-tag or MBP attached, both of which could have been used to 
facilitate further purification steps.96 Additionally, the lack of any bands present with 
high intensity at the appropriate size (~28 kDa) is likely due to autodigestion, which 
would likely begin immediately following activation.46 Potential autodigestion of AaSPII 
and AaSPIV in addition to autoactivation further contributes to difficulties associated 
both with purifying the enzymes and downstream experiments to perform activity assays 
and obtain kinetic data.44 
3.4 Alternative Purification Approaches  
In an effort to achieve purification of the recombinant enzymes, while preventing 
previously observed autoactivation and autodigestion, several alternative purification 
approaches will be pursued. Previous purification methods used buffers with pH values 
within the same range as that associated with optimal trypsin activity (pH 7–8).41 Since 
enzyme activity is often dependent on pH, later purification processes will use low pH 
buffer systems in an effort to prevent the recombinant proteases from being active and 
avoid autoactivation that may occur during the purification preparation process.41 An 
initial attempt using this strategy focused on two cation exchange columns: (1) a CM 
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weak cation exchange column using 50 mM sodium acetate, pH 5.2 to purify 
MBP-AaSPII expressed in SHuffle T7 cells grown at 15 ºC for 48 h in LB media (Figure 
34) and (2) an SP strong cation exchange column using 50 mM acetic acid, pH 4.3 buffer 
to purify MBP-AaSPIV expressed in SHuffle T7 cells grown at 15 ºC for 48 h in LB 
media (Figure 35).  
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Figure 34. 4-12% BIS-TRIS Gel analysis of fractions collected from purification via FPLC using a CM weak cation exchange 
column in 50 mM sodium acetate, pH 5.2 buffer of MBP-AaSPII expressed in SHuffle T7 cells grown at 15 ºC for 48 h in LB 
media. Lanes 1 and 17 are the protein Molecular Weight (MW) ladder (Thermo Scientific PageRuler, in kDa). From left to 
right, other lanes include total and soluble samples, two subsequent flow through samples (FT 1 and FT 2), and elution 
samples labeled according to the corresponding location in the 96-well collection microplate. Total, soluble, and the first flow 
through (FT 1) samples show target protein expression at the expected MW region (~75 kDa). 
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Figure 35. 4-12% BIS-TRIS Gel analysis of fractions collected from purification via 
FPLC using a SP cation exchange column in 50 mM acetic acid, pH 4.3 buffer of 
MBP-AaSPIV expressed in SHuffle T7 cells grown at 15 ºC for 48 h in LB media. Lane 
1 is the protein Molecular Weight (MW) ladder (Thermo Scientific PageRuler, in kDa). 
From left to right, other lanes include total and soluble samples, two subsequent flow 
through samples (FT 1 and FT 2), and elution samples labeled according to the 
corresponding location in the 96-well collection microplate. Total, soluble, and the first 
flow through (FT 1) samples show target protein expression at the expected MW region 
(~75 kDa). 
Analysis of fractions collected throughout the purification using these two cation 
exchange strategies [(1) CM weak cation exchange (Figure 34) and (2) SP strong cation 
exchange (Figure 35)] suggest that the recombinant, MBP-tagged enzymes remain 
soluble and do not autoactivate at low pH. However, the MBP-fusion proteins of interest 
eluted in the flow through (FT 1) indicating that the fusion proteins did not interact with 
either column. Interestingly, it appears that using pH 5.2 is enough to reduce and 
potentially eliminate protease autoactivation, resulting in a more positively-charged 
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histidine residue in the active, which would no longer act as an effective proton acceptor 
to generate the active site serine alkoxide ion needed for catalytic activity.42 While 
autoactivation appears to have been prevented, it also seems that other bacterial proteins 
in the lysate have also eluted in the flow through; despite the enzymes remaining inactive 
during both purification attempts (Figures 34 and 35), purification at low pH does not 
seem to be an effective method of removing excess bacterial proteins. Perhaps in 
combination with other purification methods, this could be used for an initial, crude 
purification step or purification attempts with even lower pH buffers could be used with a 
strong cation exchange column. Since the MBP-fusion complex has a calculated pI value 
of 5.50 (MBP-AaSPII) or 5.38 (MBP-AaSPIV), lowering the pH even further to achieve 
tighter binding of the complex to the column would result in a later elution time for the 
complex. 
Because purification via FPLC using DEAE anion exchange column in 20 mM Tris-
HCl, pH 8 buffer of MBP-tagged AaSPII or AaSPIV (Figures 29 and 30) resulted in both 
the MBP and the recombinant enzymes eluting in later fractions (not the flow through), it 
may be a more effective method of purification, only if autoactivation can be prevented. 
Therefore, this purification procedure was re-attempted under the same conditions with 
the addition of 1 mM phenylmethylsulfonyl fluoride (PMSF) to the crude lysate 
preparation. PMSF is an irreversible, covalent serine protease inhibitor and adding it to 
the purification buffer should prevent any potential autoactivation and subsequent 
digestion from occurring. Results of this purification were assessed via SDS-PAGE 
(Figure 36) and Western blot (Figure 37).  
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Figure 36. 4-12% BIS-TRIS Gel analysis of fractions collected from purification via FPLC using DEAE anion exchange 
column in 20 mM Tris-HCl, pH 8 buffer of MBP-AaSPIV recombinant protease expressed in SHuffle T7 cells grown at 15 ºC 
for 72 h in LB media and prepared with 1 mM PMSF added to the crude lysate preparation. Lanes 1 and 24 are the protein 
Molecular Weight (MW) ladder (Thermo Scientific PageRuler, in kDa). From left to right, other lanes include total and soluble 
samples, two subsequent flow through samples (FT 1 and FT 2), and elution samples labeled according to the corresponding 
location in the 96-well collection microplate. Only the total sample shows target protein expression at the expected MW region 
(~75 kDa). 
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Figure 37. Western blot analysis of fractions obtained from purification attempt via FPLC using DEAE anion exchange 
column in 20 mM Tris-HCl, pH 8 buffer of MBP-AaSPIV (with leader) expressed in SHuffle T7 cells grown at 15 ºC for 72 h 
in LB media and prepared with 1 mM PMSF added to the crude lysate preparation. Lane 1 is the protein Molecular Weight 
(MW) ladder (Thermo Scientific PageRuler, in kDa). From left to right following the ladder, lanes include total and soluble 
samples, two subsequent flow through samples (FT 1 and FT 2), and elution samples labeled according to the corresponding 
location in the 96-well collection microplate. Total, soluble, and fractions B5, B9, C2, and C7 show His6-tagged protein 
expression at a much lower MW region than expected (~50 kDa observed, ~75 kDa expected). 
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As shown in Figures 36 and 37, results from this purification of MBP-AaSPIV (with 
leader, expressed in SHuffle T7 cells grown at 15 ºC for 72 h in LB media via FPLC 
using a DEAE weak anion exchange column in 20 mM Tris-HCl, pH 8 buffer with the 
addition of 1 mM PMSF to the crude lysate preparation) were quite unexpected: analysis 
of sample fractions shows that cleavage of the MBP-tagged protein still occurs despite 
addition of PMSF, yielding a His6-tagged protein region consistent in size with the 47 
kDa His6-tagged MBP expected after autoactivation. PMSF is an effective irreversible 
serine protease inhibitor so it is unclear why this recombinant enzyme would remain 
active after addition of PMSF to the purification buffer and appear to have no effect on 
limiting autoactivation. However, it has been suggested that PMSF is not as specific for 
serine proteases as is often assumed and there are examples of serine proteases that are 
not inhibited by PMSF.100 Results from a qualitative activity assay (not shown) using 
BApNA showed that trypsin activity in fractions associated with this purification attempt 
(Figure 36) was not inhibited by the presence of PMSF. Also, predictions of protease 
function based on sequence analyses are sometimes found to be incorrect upon obtaining 
experimental functional data so it may be possible that AaSPII or AaSPIV are not 
trypsin-like enzymes despite sequence alignments suggesting so; while sequence analyses 
can be powerful tools for designing experimentation and predicting results, assumptions 
based on sequence homology assessments are somewhat uncertain until enzyme function 
and structure are experimentally determined.82,101 Previous study of one of the abundant 
Ae. aegypti serine proteases, late trypsin (AaLT), found that, despite identification of 
AaLT as a trypsin based on deduced amino acid sequence and sequence alignment data, 
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reduction of AaLT transcripts did not result in a loss of trypsin-like activity, as was 
predicted.22 It was later determined that AaLT lacked the necessary aspartate residue at 
position 189 necessary for substrate recognition and specificity of trypsins and, based on 
structural modeling data, AaLT is likely to be more accurately defined as a serine 
collagenase and not a classic trypsin.23,35 
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CHAPTER 4: CONCLUSIONS 
4.1 AaSPIV Genome Sequence 
Initial attempts taken to isolate the AaSPIV gene from Ae. aegypti cDNA led to the 
presence of two specific nucleotide changes that resulted in specific amino acid changes 
with respect to the annotated sequence at position 162 (a lysine to a glutamate residue) 
and at position 288 (a lysine to an arginine).35 Repeating the isolation of the AaSPIV 
gene from a freshly prepared batch of Ae. aegypti whole body mosquito cDNA confirmed 
that these changes are indeed consistent with results from initial cloning attempts. This 
indicated potential misannotation of the gene sequence in public databases or differences 
due to genetic variability of the Ae. aegypti species; it is possible that these two residues 
are nonessential for function or flexible in the electrostatic or steric property requirements 
for proper folding and activity and therefore are not highly conserved. Hence, these 
specific inconsistencies between the AaSPIV gene sequence cloned into each plasmid 
construct and the annotated AaSPIV gene sequence were disregarded for all later 
experiments and studies herein proceeded; upon solving the structure of AaSPIV, the 
identity of these two amino acid residues may be confirmed and their role in the 
enzyme’s structure and function can be further assessed to determine if they are expected 
to be highly conserved.  
4.2 Recombinant Protein Expression 
All growth experiments were performed using SHuffle T7 E. coli cells to aid in 
proper folding of recombinant AaSPII or AaSPIV. Both of these mosquito proteases are 
predicted to contain four disulfide bonds and this engineered bacterial species is designed 
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to have a more oxidized cytosolic environment and it expresses a disulfide bond 
isomerase (DsbC) to aid in forming native disulfide bonds when cysteine residues are 
mis-bonded.69 Several growth experiment conditions resulted in the insoluble expression 
of the target enzymes: AaSPII (no leader)-pET28a construct (N-terminally His6-tagged) 
grown at 10 ºC using TB media (Figure 17) or in auto-induction media (Figure 19); 
AaSPIV (with leader)-pET28a construct (N-terminally His6-tagged) grown at 10 ºC in TB 
media (Figure 18) or in auto-induction media (Figure 20); and AaSPII-pET28a with the 
EK-pseudo propeptide region construct (N-terminally His6-tagged) grown at 15 ºC in 
auto-induction media (Figure 22). Surprisingly, when this construct was grown at a 
higher temperature (30 ºC for 24 h) soluble expression was observed (Figure 23). 
Additionally, total expression levels for each of these growth experiments did not appear 
to be very high compared to the naturally expressed bacterial proteins. In biochemically 
studying a target protein, large yields of solubly expressed protein are necessary since 
large quantities are required for activity assays or structure determination. Therefore, 
further experimentation was performed in an attempt to achieve solubly expressed 
AaSPII and AaSPIV recombinant proteases.47 
After a multitude of growth experiments aimed at optimizing conditions for 
recombinant protein expression, I was able to establish a highly effective method for 
expressing significant concentrations of soluble recombinant proteases. For both AaSPII 
(no leader) and AaSPIV (with leader), soluble recombinant protein expression was 
achieved by expressing each enzyme as an MBP-fusion tag using the pMAL-c5E vector. 
Specifically, soluble expression was maximized using the following conditions: 
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MBP-tagged AaSPII without the leader sequence (MBP-AaSPII) and MBP-tagged full 
length AaSPIV with the leader sequence (MBP-AaSPIV) were expressed using SHuffle 
T7 E. coli cells grown in LB media at 15 ºC for 24 h (MBP-AaSPII; Figure 24) or for 
48 h (MBP-AaSPIV; Figure 25). Growth experiments using the pMAL-c5E constructs 
were consistently successful in producing high levels of total and soluble target protein 
and were not drastically affected by lowering the growth temperature as far as 10 ºC or 
extending growth times to up to 96 h (results not shown). For these reasons, we focused 
on the soluble expression of the MBP-fusion proteases for later purification experiments.  
4.3 Possible Autocatalytic Activity of AaSPII and AaSPIV 
Purification attempts seem to indicate that AaSPII and AaSPIV may be 
autoactivating44: (1) results of the SDS-PAGE analysis of fractions collected from the 
purification of MBP-AaSPIV using the wheat starch purification method (Figure 27); (2) 
results of the SDS-PAGE analysis of fractions collected from the purification of 
MBP-AaSPII via FPLC using a DEAE anion exchange column in 20 mM Tris-HCl, pH 8 
buffer (Figure 29); and (3) results of the SDS-PAGE (Figure 30) and (4) Western blot 
(Figure 31) analyses of fractions collected from the purification of MBP-AaSPIV via 
FPLC using a DEAE anion exchange column in 20 mM Tris-HCl, pH 8 buffer. It is also 
likely that the proteases undergo autodigestion in addition to autoactivation. Trypsin 
activity was observed using the qualitative activity assay with BApNA (Figure 33) to 
assess fractions collected from the purification of MBP-AaSPIV via FPLC using a DEAE 
anion exchange column in 20 mM Tris-HCl, pH 8 buffer, but in the complementary 
SDS-PAGE analysis (Figure 30) there were no discernable bands present in the expected 
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region of the gel associated with the free, active protease (~28 kDa), suggesting 
autodigestion. This, in combination with the known challenges associated with 
expressing disulfide-bonded proteins in E. coli49, would explain much of the difficulty 
experienced in both the expression and the purification processes. Despite challenges 
presented in attempts to purify the recombinant enzymes, the results of purification 
experiments are suggestive of both autocatalysis and autodigestion. Additionally, 
purification attempts using lower pH buffers indicate the pH-dependence of protease 
activity. While purified proteases were not obtained for use in kinetic or structural 
studies, the potential autocatalysis, autodigestion, and pH-dependence of these proteases 
provide further insight into the potential roles of AaSPII and AaSPIV in Ae. aegypti 
blood meal digestion; because these enzymes are expressed constantly following blood 
meal acquisition35, we hypothesize that they may be responsible for the initial digestion 
of blood meal proteins to promote accessibility of internal peptide bonds for further 
digestion by other midgut serine proteases.   
4.4 Future Studies 
Due to difficulties in obtaining purified recombinant proteases, which are likely due 
to autoactivation and autodigestion during the purification preparation process, 
immediate future studies will focus on growth experiments to express recombinant 
AaSPII (no leader) and AaSPIV (with leader) with the mutated active site serine to 
alanine using both pET28a and pMAL-c5E constructs. This should lead to inactive 
proteases incapable of autoactivating and autodigesting and prevent the associated 
obstacles observed during the purification of the wildtype AaSPII and AaSPIV fusion 
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proteins. However, mutating the active site serine residue would lead to inactive 
proteases, making downstream kinetic assays impossible, but could be useful for 
obtaining structural data. 
Additionally, primers were developed to mutate the lysine residue to alanine at the 
propeptide region. This region is necessary in order to convert the inactive zymogen to 
the active mature enzyme, and for both AaSPII and AaSPIV, the propeptide cleavage 
amino acid is lysine. By mutating this lysine residue, this may prevent autoactivation and 
allow for later in vitro activation of the enzyme for functional studies.  
Expression of the recombinant enzymes with the engineered EK-pseudo propeptide 
was also attempted to prevent autoactivation; however, trypsin-like enzymes prefer to 
cleave on the C-terminal peptide bonds of lysine or arginine residues, so the EK region 
may still be a suitable target for AaSPII and AaSPIV autoactivation. However, results of 
AaSPII with the EK-pseudo propeptide construct in SHuffle T7 cells grown using auto-
induction at 30 ºC did show successful expression with limited or no autoactivation 
(Figure 21). However, repeated growth experiments using the same conditions or with 
lowered temperatures and extended growth times were all unsuccessful (results not 
shown). Further efforts to repeat the successful soluble expression observed in Figure 21 
need to be taken. Issues obtaining soluble expression of the proteases containing the 
EK-pseudo propeptide could likely be overcome with the addition of an MBP-fusion tag. 
Each of the pET28a plasmid constructs encoding AaSPII and AaSPIV with the attached 
EK-pseudo propeptide can be used as templates for cloning into the pMAL-c5E vector as 
described in the Methods section for the AaSPII (no leader) and AaSPIV (with leader) 
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constructs. This would allow for expression of MBP-tagged recombinant proteases with 
both an internal His6-tag and EK-pseudo propeptide region, which would hopefully result 
in highly expressed inactive recombinant enzymes that could be easily purified and later 
activated in vitro (this step could be used to both activate the enzyme and also remove the 
attached MBP and His6-tag). In order to fully understand the biological role of AaSPII 
and AaSPIV in the Ae. aegypti blood meal digestion process, it will be necessary to 
circumvent certain difficulties in the expression process in order to obtain kinetic data 
and provide insight into the enzymes’ functions.  
Of the discussed experiments, purification via FPLC using a DEAE weak anion 
exchange column in 20 mM Tris-HCl, pH 8 buffer with the addition of 1 mM PMSF 
needs to be repeated with both MBP-tagged proteases to confirm consistency and 
repeatability of the results, especially based on the potential implications of ineffective 
inhibition of these proteases by PMSF. At this point, purification with PMSF added was 
only performed once and only with MBP-tagged AaSPIV (with leader). Because PMSF is 
an irreversible inhibitor of serine proteases, its use in the purification process would 
prevent later activity studies (as is the case for potential expressed proteases with an 
active site serine mutated to an alanine). Therefore, these methods could be used to obtain 
inactive but properly folded recombinant enzymes suitable for structural studies via 
crystallography. Additionally, purified inactive soluble recombinant proteases could be 
used in binding studies to determine binding specificity.  
If later experiments confirm that PMSF is not an effective inhibitor against active 
AaSPII or AaSPIV, the addition of other inhibitors can be used to both achieve purified 
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inactive proteases and determine what type of inhibitors are effective against the 
proteases, which would also provide insight into the enzyme function. Another method to 
potentially inactivate the recombinant proteases expressed as MBP-fusion proteins would 
be to include a reducing agent such as dithiothreitol (DTT) in the purification buffer to 
counterbalance the effects of MBP as a solubility enhancer; expression with MBP could 
assure that solubility of the recombinant proteases is achieved while reduction of the 
disulfide bonds may be enough to minimize activity while maintaining solubility. 
Purification efforts at lower pH values (Figures 34 and 35) implied the pH-dependence of 
the proteases, which can be further explored to obtain pH profiles for each protease by 
determining if autocatalyzation also occurs at higher pH values or if pH-dependence is 
parallel to that of classic trypsin.  
If the enzymes are autocatalyzing and potentially autodigesting, determining potential 
internal cleavage sites within the active proteases would be extremely informative. 
Cloning of the AaSPII and AaSPIV genes were both cloned into the pET29b vector, 
which encodes for a C-terminal His6-tag. Further growth experiments will be performed 
to determine the optimal conditions for producing soluble, recombinant enzyme with a 
C-terminal His6-tag; if subsequent purification results also suggest autocatalytic behavior, 
the cleaved protein product will still be purified by exploiting the His6-tag for IMAC. 
Cleaved proteins and protein species could then be verified using N-terminal sequencing 
and confirm specific internal cleavage sites, providing valuable information on potential 
substrate recognition and specificity. 
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